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ABSTRACT 
Co-treatment of Doxorubicin (dox) with plant flavonoid-type antioxidants, morin 
(mor) and quercetin (que), has been studied. Doxorubicin is a well-known potent anticancer 
drug against a wide range of human malignant neoplasms. It kills the cancer cells through 
radical-independent and radical-dependent mechanisms. In the radical-independent 
mechanism, which is dominant in the anticancer effect’ doxorubicin kills the tumor cells by 
intercalating with their DNA molecules and inhibiting the topoisomerase H In the radical-
dependent mechanism, doxorubicin kills the tumor cells through generation of oxyradicals in 
its metabolism in the cells. However, these oxyradicals cause damages not only in tumor cells, 
but also in normal cells especially the myocardial cells. These oxyradicals may overwhelm the 
limited capacity of cardiac muscle to detoxify free radicals, resulting in extensive peroxidative 
damage to myocardial cells. Moreover, doxombicin-resistance will develop in tumor cells after 
prolonged dox-treatment. Therefore, apart from side effects that are common to cancer 
chemotherapeutics, the usefulness of doxorubicin is, however, limited by cumulative dose-
related cardiomyopathy as well as drug resistance. 
Morin and quercetin are highly effective scavengers of all types of oxidizing radicals 
due to their metal-chelating and oxyiadical scavenging properties. They can form complex 
with metal ions or donate hydrogen atom to form flavonoid radical with low reduction 
potential. In m in viw study, we found that Sprague-Dawley (SD) rats treated with 
doxorubicin together with morin or quercetin exhibited significantly less heart damages than 
the group treated with doxorubicin only. Decreases of 38% and 57% in heart thiobarbituric 
acid reactive substances (TEARS) contents were found respectively in morin- and quercetin-
co-treatments. Heart malondialdehyde (MDA) levels showed 187% and 200% decreases in SD 
rats treated with morin and quercetin respectively. However, no induction of antioxidant 
defense enzyme system was observed. Therefore, this cardioprotective effect seemed mainly 
due to the scavenging effect of morin and quercetin. Furthermore, it is shown in the tumor-
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bearing model that morin and quercetin enhanced the antitumor effect in doxorubicin 
chemotherapy in the host and their hearts were also found to be protected. 
In addition, morin did not reduce the cytotoxicity of doxorubicin on the human 
hepatoma (HepG2) cells invitm. Quercetin showed cytotoxic effect on both HepG2 and R-
HepG2 cells. It exhibited synergistic effect with doxorubicin on the killing effect on HepG2 
and R-HepG2 cells. By Western hybridization, we found that morin and quercetin could also 
reduce the expressions of glutathione transferase (GST) and p-glycoprotein, which are 
involved in the mechanism of drug resistance. 
To conclude, morin and quercetin could protect the heart from doxorubicin-mduced 
damage，and at the same time, enhance the cytotoxic effect. Moreover, they could reduce the 
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Cancer Killing mechanism 
Doxorubicin (adriamycin) is a quinone-containii^ antitumor antibiotic, originally 
isolated from the fungus Streptomyoespei^ (Arcamone etd., 1972). It is a chemotherapeutic 
agent with strong activity against a wide range of human malignant neoplasms. It consists of 
a water-insoluble tetracycline aglycone and a water-soluble reducing daunosamine sugar (Fig. 
U) . Several parts of the doxorubicin molecule can be metabolized and involved in the free 
radical-dependent antitumor mechanisms. Doxorubicin has two cancer cell-killing 
mechanisms ordinarily. One is free radical dependent, and the other is free radical-
independent. The free radical-dependent antitumor mechanism involves metabolic activation 
of doxorubicin firstly (Fig. 1.2). Ring C in doxorubicin is one-electron reduced by cellular 
flavoproteins, with donation of electrons by NADH or NADPH, to form its reduced 
semiquinone form. In the presence of oxygen, the semiquinone free radical is oxidized back 
into the parental quinone form under formation of superoxide radicals. In the absence of 
oxygen，the semiquinone loses its sugar moiety and then forms an intermediate C7 free 
radical. 
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Fig. 1.2 Metabolism of doxorubicin (Keizer et al” 1990). 
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Moreover, in the presence of iron, formations of a doxombicin-Fe^^ complex occur 
through the oxidation in ring B (Gianni et d., 1985; Zweier, 1985). In the presence of 
reducing system, the doxorubicin-Fe^^ complex is reduced either enzymatically by NADH 
cytochrome P-450 reductase (Sugioka and Nakano, 1982) or by thiols like glutathione (GSH) 
or cysteine (Zweier, 1985). The doxombicin-Fe'^ complex will then react with oxygen to 
generate superoxide radicals. No metabolites are formed and the free radical production can 
proceed indefinitely. In the absence of reducing system, doxombicin-Fe'^ can reduce its 
chelated iron by an intramolecular redox reaction (Zweier etal., 1986; Gianni ad., 1988; Fig. 
1.3)，forming doxorubicin free radical chelating with Fe^ "^  (Gianni etal” 1985; Zweier 过义， 
1986; Zweier et d” 1985). This complex can be oxidized, generating superoxide radical 
(Gianni et d” 1985) or react with hydrogen peroxide via formation of hydroxyl radicals 
(Zweier，1985; Muindi ‘ 1984,1985). Electrons from the C9 side chain of doxorubicin 
keep the iron of the complex reduced and thus support free radical production until the side 
chain is fully oxidized fomiing 9-dehydrox7acetyl-9-carbox)d doxorubicin (9-CC)OH-
doxorubicin) (Gianni e?^/., 1988). 
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The doxorubicin metabolites CZ-quinone methide and C7 free radical can cause 
DNA damage by alkalytion and covalendy bind to the DNA respectively. The superoxide 
radicals generated in doxorubicin metabolism may undergo a non-enzymatic or superoxide 
dismutase (SOD)-catalyzed reaction, producing non-radical hydrogen peroxide (HjOj). Fe^ ^ 
or Cu+ may oxidize the hydrogen peroxide after the hydrogen peroxide has crossed the cell 
membrane, and hydroxyl radical will be formed This is Fenton reaction. The hydrogen 
peroxide may also react with superoxide to form hydroxyl radical in the presence of iron or 
copper complex (Haber-Weiss reaction). The oxygpn reactive species (ROS) generated in the 
metabolism of doxorubicin have potent oxidative stress. They can react with a wide variety 
of biomolecules, including DNA, protein and lipid, eventually causing dam^es to the cells. 
The ROS induce DNA strand breakage and chemical modification of the bases in DNA. 
Moreover, ROS can attack protein by oxidizing the amino acid chains, forming covalently 
cross-linked protein aggregates and fragmentizing the polypeptide chain. Hydrogen peroxide 
can inactivate some enzymes. Such attack of protein may result in alterations of signal 
transduction mechanisms, transport systems, and en2yme activities, thus disturbing the 
normal metabolism of the cells. Biomembranes composing of phospholipid bilayers with 
proteins are one of the major targets of reactive oxygen species, the attack of which affects 
membrane functions by inducing continuous lipid peroxidation. Lipid peroxidation involves 
a radical chain reaction，which consists of a chain-initiation reaction and a chain-propagation 
reaction (Fig. 1.4). The process is initiated when free radicals abstract hydrogen from 
polyunsaturated fatty acids (PUFA) to form fatty acid radicals. The biologically active lipid 
peroxy radicals can react with other lipids，proteins, or nucleic acids and thereby propagate 
the transfer of electrons and subsequent oxidation of substrate. These oi^anic radicals 
perpetuate a chain reaction by attacking additional side chains, leading to formation of lipid 
peroxides. The peroxidation of lipids causes changes in membmne fluidity and 
semipermeable characteristics of membranes (Esterbauer, 1986). 
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In addition to DNA, protein damages and lipid peroxidation caused by free radicals 
generated in the metabolism of doxorubicin metabolism, there is a free radical-independent 
mechanism involved in the antitumor effect of doxorubicin. The most widely studied 
nonradical-dependent mechanisms of cytotoxicity are based on the capacity of drug 
intercalating into double-stranded DNA. As a consequence, it inhibits both RNA and DNA 
synthesis，a process which might be involved in its antitumor effect (Aubel-Sadron and 
Londos-Gagjiardi, 1984). Apart from DNA intercalation, a novel mechanism by which 
doxorubicin may kill tumor cells has been described. It is based on interference with the 
D N A breakage-reunion reaction mediated by topoisomerase 11 (Tewey et al” 1984). 
Although free radical generated in doxorubicin metabolism posses potent cellular 
damaging effect, many tumor cell types are not killed by such free radical-dependent 
mechanism. The free radical-independent mechanism dominates the cytotoxicity of 
doxorubicin. However, the free radical-dependent mechanism causes lethal, dose-dependent 
and cumulative side effects on myocardial tissue of the host in chemotherapy of doxorubicin. 
Adverse side effects of doxorubicin 
Apart from side effects that are common to many cancer chemotherapeutics, Le. 
hematopoietic suppression, nausea and vomiting, and alopecia, the clinical usefulness of 
doxorubicin is limited largely hy a cumulative dose-related cardiomyopathy that manifests 
itself as congestive heart failure (Young et al” 1981). 
Doxorubicin metabolized to generate free radical metabolite mainly in cardiac 
mitochondria and in liver and cardiac microsomes (Thayer et^., 1977 and Bachur^^., 1978). 
In liver microsomes, doxorubicin semiquinone radicals react preferentially with molecular 
oxygen to form relatively less harm superoxide radicals. On the other hand, semiquinones 
formed in heart mitochondria and microsomes appear to react rather with hydrogen peroxide 
with formation of the highly reactive hydroxjd radical (Nohl and Jordan, 1983). Therefore, 
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lai^e amount of highly reactive hydroxyl radicals is formed and then cause lipid peroxidation 
in cardiac tissue after doxorubicin administration. However, the doxombicin-induced 
cardiomyopathy is not only the result of the relative abundance of mitochondria, and efficient 
hydroxyl radical formation in cardiac tissue as discussed above, but also of a relatively poor 
antioxidant defense. Heart has rather low levels of superoxide dismutase and catalase 
poroshow et al., 1980) and a relatively low rate of glutathione turnover when compared to 
liver tissue (Griffith and Meister，1979). 
Several approaches have been developed in order to prevent the doxombicin-induced 
side effect on myocardial tissue. Different treatment schedules aimed to decrease plasm and 
myocardium drug levels (Torti etal., 1983). Anthracycline analogs devoid of cardiac toxicity 
were investigated (Bonfante etal., 1986). Combined treatments with ^ents to interfere with 
one or more of the mechanisms involved in the development of cardiomyopathy were also 
studied (Gabrecht et al” 1986 and Herman et al” 1986). 
In this project，combined treatment with the antioxidant flavonoids to minimize the 
development of doxombicin-induced cardiomyopathy was studied. 
Drug resistance 
The development of doxorubicin resistance is another limitation of the use of 
doxorubicin in chemotherapy. Several mechanisms that mediate such resistance have been 
described. First, p-glycoprotein (Gottesman and Pastan, 1988) and multidrug resistance-
associated protein (MRP) (Cole etoL, 1992)： they afford increased rates of drug efflux from 
the cell, so that doxorubicin interacts with the tumor cells to a reduced extent. Second, 
decreased drug sensitivity: it is done either by elevating levels of the target to overcome 
doxorubicin doses, or mutating the target, thus rendering the drug ineffective (e.g. 
dihydrofolate reductase) (Schimke, 1984). Third, increased DNA repair mechanism: Q 、 
altylguanine transferase activity is elevated to reverse doxorubicin cytotoxicity (Pegg and 
Byers，1992). And last, altered expression of metabolic and detoxification processes that 
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protect the cell against doxorubicin dam^e: this may be mediated by the glutathione/ 
glutathione transferase (GSH/GST) detoxification system. It has already been reported that 
doxorubicin resistance is associated with increased glutathione levels and glutathione-S-
transferase activities. 
In this research, the effect of morin and quercetin on the doxorubicin resistance will 




Oxidants or reactive oxygen species (ROS) is a collective term that includes not only 
oxygen-derived radicals, such as superoxide and hydroxyl radicals, but also some non-radical 
oxygen derivatives, such as hydrogen peroxide and hypochlorous acid Although oxidants 
damage tissues by causing lipid peroxidation, oxidation of protein thiol groups and strand 
scission of DNA (Freeman and Crapo, 1982; Thompson and Hess, 1986; Wesis, 1986; Cross, 
1987; Ferrari et oL, 1991), their generation is always an unavoidable consequence under 
normal physiological processes. Seeing the continuous generation of oxidants by constitutive 
metabolic pathways, endogenous protective systems have evolved These systems, which 
involve enzymatic antioxidants and non-enzymatic antioxidants, ensure the maintenance of 
metabolic and functional performance as well as cell and organ viability. The delicate balance 
between the production and catabolism of oxidants is critical for the maintenance of 
biological functions. When this balance is upset, either by overproduction of ROS and/or 
reduced effectiveness of the defense mechanism, various pathological manifestations can 
occur. 
Enzymatic antioxidants 
1. Superoxide dismutase (SOD) 
Superoxide dismutase is a metal protein (McCord and Fridovich, 1968) catalyzing the 
conversion of superoxide into hydrogen peroxide. 
20；- +2H • H A + O 2 
There are several different types of SOD, each containing a different metallic prosthetic 
group. Copper and zinc containing superoxide dismutase (Cu2n-SOD) which is present in 
the cytosol and magnesium containing superoxide dismutase (Mn-SOD) which is present in 
the mitochondria (Freeman and Crapo, 1982; Lunec etal” 1982) are the most common. The 





Catalase is a cytoplasmic heme eii2yme which catalyzes the reduction of hydrogen 
peroxide to water and oxygen molecules. 
H2O2 + H2O5 • 2H2O+ O2 
It is a tetrameric protein of molecular weight of approximately 240,000. This enzyme is 
effective at millimolar concentration of hydrogen peroxide, while glutathione peroxidase plays 
important role at micromolar concentration. The concentration of catalase in the heart is 
reported to be relatively low poroshow et al” 1980). 
3. Glutathione peroxidase 
Glutathione peroxidase (GPx) is located mainly within the cytosol of ajkaiyotic cells 
but may also be present intramitochondrially. It is a tetrameric protein of total molecular 
weight approximately 84,000 consisting of four identical subunits. Each subunit has one 
selnocysteine residue, which is the catalytic element of GPx, firmly integrated into the protein 
backbone. GPx is important for the detoxification not only of hydrogen peroxide but also of 
organic peroxides. 
H2O2 + 2GSH • GSSG + 2H2O 
ROOH + 2GSH • GSSG + ROH + 即 
Cardiac tissue is veiy rich in this enzyme. Glutathione peroxidase is more effective at low 
concentration (10'^  to 10"^  M) of hydrogen peroxide. Apart from selenium-dependent GPx, 
there is also selenium-independent GPx, which detoxifies organic peroxides but does not 
metabolize hydrogen peroxide (Lawrence and Burk, 1978). The relative importance of the 
two forms of GPx may be determined by the type and source of oxidant stress to which 
individual tissues are subjected. 
4. Glutathione transferase 
Glutathione transferases (GST) are a family of multi-functional proteins which act as 
enzymes and also as binding proteins in detoxification processes. Most glutathione 
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transferases are located in the cytosol, and are grouped into five classes, Alpha, Mu, Pi, Theta 
and Sigma. They catalyze the conjugation of glutathione with a variety of organic peroxide. 
Some forms of glutathione transferase have selenium-independent glutathione peroxidase 
activity towards lipid hydroperoxides. 
Non-enzymatic antioxidants 
There is a whole variety of biological molecules that can act as antioxidants by either 
quenching a free radical directly, or indirectly, promoting a process responsible for radical 
scavenging. 
1. Glutathione 
Glutathione, which is a tripeptide, is present in high concentrations in most 
eukaiyotic cells. It exhibits antioxidative effect in two ways. First, it may aa as a reductant to 
reduce ROS, such as hydrogen peroxide, directly to water, forming oxidized glutathione 
(GSSG) under the catalysis of selenium-dependent glutathione peroxidase (Ross et al., 1985) 
in most cells. 
H2O2 + 2GSH • • GSSG + 2 H P 
Second，it may react direactly with such free radicals as superoxide, hydroxyl radical and 
o — c radicals by a radical transfer process yielding thiol mdical of glutathione, and 
eventually oxidized glutathione. 
To regenerate the reduced form glutathione, glutathione reductase is involved 
Glutathione reductase (GRD) exhibits its metabolic function of supplying the reduced form 
glutathione (GSH) by catalyzing the irreversible reduction of the oxidized glutathione (GSSG) 
by NADPH. 
GSSG + 2 N A D P H ~ ^ ^ 2GSH + 2NADP+ 
This enzyme contains FAD and redox-active disufide at the active center and is located in the 




Alpha-tocopherol (Vitamin E) is present in relatively high concentrations in both cell 
and mitochondria membrane. It can scavenge and terminate free-radical reactions and form 
tocopherol dimmers or quinones. Vkamin E reacts with reactive oxygen metabolites, yielding 
lipid hydroperoxides which can be removed by the activity of the phospholipase-GPx system. 
This reaction is believed to interrupt the radical chain reaction processes that propagate 
peroxidation of membranes. Moreover, Vitamin E functions synergistically with ascorbic 
acid to terminate free-radical reactions. 
3. Ascorbic acid 
Ascorbic acid (Vitamin C) is present in micromolar concentrations in the cytosol and 
in serum. It reduces reactive oxygen metabolites directly in aqueous phase, with the 
concurrent formation of dehydroascorbate, and/or indirectly, by the regeneration of 
tocopherol from the tocopherol radical (Packer etd” 1979). However, Vitamin C will react 
with trace metal ions such as Fe^ ^ and Cu^ "" to yield reactive oxygen metabolites. 
4. Uric acid 
It is possible that the metabolic waste product uric acid has some antioxidant 
property. Urate can interact directly with reactive oxygen metabolites such as hydroxyl radical 
{Ames etal., 1981). Moreover, it can protect human blood plasma ascorbate from oxidation 
(Sevanian et al, 1985). 
5. P-Carotene 
p-Carotene is the precursor of Vitamin A. It can quench active oxygen species and 
lipid radicals (Foote and Denny, 1968) at low-oxygen tension. It may also provide some 
synergism to Vitamin E. 
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6. Miscellaneous proteins 
Miscellaneous proteins provide varieties mechanisms that minimize the levels of free 
metal ions such as Fe^ ^ and Cu^ "" in biological systems. They play a role in host defense 
against oxidant-induced damages by slowing down the production of R〇S t h r o i ^ metal-
catalyzed reactions. Free iron concentrations in biological systems are kept low by binding to 
such storage and transport proteins as ferritin, transferring, and lactofenin. Copper 
concentrations may be modulated by ceruloplasmin, a copper-binding protein that also has 
antioxidant properties (Fantone and Ward, 1982; Blake et al., 1987). 
In addition to the conventional biological enzymatic and nonenzymatic antioxidants 
discussed above, many other drugs and chemicals can be applied to reduce or prevent 
oxidant-induced changes. 
Exogenous antioxidants 
1. Calcium antagonists 
Calcium antagonists may exhibit antiperoxidative activities against lipid peroxidation. 
Some of them can inhibit superoxide production (Kaul a d ” 1990) or scavenge superoxide 
(Westlin and MuUane, 1988)，while some can reduce production of ROS and lipid peroxides 
(Kobyashi et al., 1987). Some calcium antagonist can also inhibit lipid peroxidation by a 
chain-breaking mechanism (Mak et al., 1989) as well as show protective effect against 
doxorubicin-induced cardiomyopathy (Siveski-Iliskovic et al” 1993). 
2. Desferrioxamine 
Desferrioxamine is a high-affinity iron chelator which inhibits lipid peroxidation 
(Willis，1969). It was found to reduce the injuiy associated with ischemia and reperfusion 




p-Blockers, such as propranolol, pindolol, metoprolol, atenolol and sotalol, can 
inhibit peroxidation in a concentration-dependent manner (Weiglicki et aL, 1990). 
4. Penolic compounds 
The ability of plant polypenols to act as antioxidants in biological systems has been 
recognized since 1930s. Flavonoids are polypenolic compounds that occur ubiquitously in 
food of plant origin and possess radical-scavenging and oxidant-inhibiting effects. 
In this project，the application of flavonoids to minimize the development of 




Flavonoids are a group of C15 aromatic plant pigments, which are biosynthesized via 
a confluence of the acetate/ malonate and shikimate pathways. They are found in viituaUy all 
land-based green plants and, although not produced by animals, may occasionally be 
accumulated by them from their food sources. In plant, the flavonoids occur as white and 
yellow pigments in flowers, fruit, bark and roots, astringent parasite deterrents (Swain, 1976; 
Swain et d” 1979). They also protect the plant from harmful UV radiation from the sun. 
Since flavonoids are ubiquitously found in fruits and vegetables, it was estimated that the 
average human intake in western countries was about 23mg/day (Hertog et ai, 1993). 
Flavonoids give benefits not only to plants, but also to human. They exhibit a broad range of 
appreciative phannacological activity. Beneficial effects of flavonoids have been described 
for diabetes mellitus, allei^, cancer, viral infections, headache, stomache and duodenal ulcer, 
parodentosis, and inflammations. 
There are seven major families of flavonoids. They are flavones, flavonols, 
flavavones, flavanonol, flavanol, isoflavones and anthocyanidins (Fig. 1.5). All of them have 
similar biological properties: antioxidant, anticataraa, anti-inflammatoiy, antiallergic effects, 
antiproliferative, angiogenesis-inhibiting, hypocholesterolemic, triglycericle-lowering activity 
and inhibitii^ lipoxygenase activity. Although there are so many families and benefits in 
flavonoids, the antioxidant activity of the flavonols quercetin and morin will mainly be 
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Fig. 1.5 Subclasses of the flavonoid families. 
18 
) 
Morin and Ouercetin 
Morin and quercetin are the antioxidants studied in this project. They belong to the 
family of flavonols. The structures of them are shown in Fig. 1.6. The antioxidant activity of 
morin and quercetin has been widely studied. It was reported that they could inhibit lipid 
peroxidation in micelles (Wang and Zheng, 1992) and in rat liver microsomes (Cholbi etd” 
1991). Moreover, morin hydrate protects rat hepatocytes against oxyradical-induced damage 
in vitro and the rat liver from ischemia-reperfusion injmy (Wuet^., 1993). It was also found 
that morin protects human erythrocytes, ventricular myocytes and saphenous vein endothelial 
cells better than ascorbate and Trolox (Wu et al., 1994). The mechanism of their action 
rcktes to free radical scavenging and iron-chelating abilities acting as free radical chain-









Fig. 1.6 Structure of morin and quercetin. 
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Free radical scavenging 
To scavenge free radical, morin and quercetin have to donate a hydrogen atom and 
then form flavonoid radical. Quercetin is used as an example to illustrate the free radical 
scavenging ability. 
Flavo-O-H • Flavo-O. + H . 
This radical has high stability and thus low reduction potential. It is mainly due to (Fig. 1.7)： 
1. The o-dihydroxy structure in the B ring, which confers higher stability to the radical 
form and participates in electron delocalization; 
2. The 2,3-double bond in conji^ation with a 4-oxo function in the C ring, responsible for 
electron delocalization from the B ring (phenoxyl radicals produced are stabilized by the 
resonance effect of the aromatic nucleus); 
3. The 3- and 5-OH groups with the 4-oxo function in A and C rings, for maximum 
scavenging potential. 
The delocalization of the impaired electron and the negative charge in the quercetin radical 
dianion leads to a dramatic lowering of its reduction potential. Moreover, the negative chaise 
in the radical dianion facilitates quercetin to exhibit antioxidant effect in three other ways. 
First，the negatively charged radical is not likely to pass through the negatively charged cell 
membrane. Second, the reaction of flavonoid radical with Vitamin E, which is 
thermodynamically feasible, has an additional obstacle because of the electrostatic repulsion 
between the multiply negatively charged membrane phospholipid, where Vitamin E is 
embedded, and the flavonoid radical anion. Therefore, Vitamin E can be preserved to reduce 
other more harmful oxidants. Third, one-electron oxidation of flavonoids by any oxidant will 
have an entropic barrier, because at least two protons are exchanged in the reaction. The 
proton may be exchanged between the reactants or with the solvent in the transition state, in 
which case a hydrogen-bonded interface plays a role. Both these processes are entropically 
expensive, thus slowing down the reaction. (Isabelle et al” 1998) 
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Iron ions are necessary for life and are involved in many physiological processes, such 
as ATP generation and functioning of hemoproteins (Weinberg, 1990). However, 
overaccumuktion of them can induce an intense oxidative stress. It is because Fe，. catalyzes 
the Fenton reaction, which generates highly toxic hydroxyl radicals. Apart from scavenging 
free radical, flavonoids can complex with iron ion, which has an in complete valency shell. 
There are three possible metal-complexing sites within morin and quercetin. These are 
between the G3 hydroxyl and the carbonyl, the C-5 hydroxyl and the carbonyl, and between 
the onho-hydroxyh in the B-ring. In the formation of the complex, hydrogen at the B-rii^ is 
abstracted during the scavenging reaction with oxyiadicals. The complex is stable because of 
the extensive electron delocalization within the flavonoid radical-iron complex. Therefore, 
the oxidative stress may be released. 
In addition to radical scavenging and iron chelating activities, the hydrophilic property 
of flavonoid facilitates itself to act as unique antioxidants in phospholipid bilayers. It can 
localize at the interface of the bilayers and thereby inhibits initial attack by aqueous radicals 
effectively (Fig. 1.8). 
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Fig. 1.8. Role of flavonoids in the defense against oxidative damage 
(Junji and Mariusz, 1997). 
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1.4 Protection against doxorubicin-induced cardiotoxicity by antioxidant 
The applications of antioxidants to protect against doxorubicin-induced 
cardiomyopathy have been studied for a long time. Mice treated with Vitamin E were found 
to be less susceptible to doxorubicin-induced cardiotoxicity (Myer, et d” 1977). Recendy, it 
was also demonstrated that derazoxane (DZR)，which is an intracellular chelator, could 
protect weanling rats from heart damage after doxorubicin treatment (Paola et ‘，1999). The 
flavonoid catechin was also studied and demonstrated to possess significant cardioprotective 
effect gainst doxorubicin toxicity (Osman etoL, 1996). In vitro, the co-incubation of morin 
hydrate with doxorubicin was found to minimize the cardiotoxicity side effect of doxorubicin 
(Kok et al., 2000). Although the idea of using antioxidant to minimize the doxombicin-
induced cardiomyopathy has been well demonstrated, their in izuo effect on affecting the 
antitumor activity of doxorubicin has seldom been studied. In my research, the effect of 
morin and quercetin on doxorubicin antitumor activity as well as on the cardiotoxicity side 
effects was demonstrated. 
1.5 Aim of research 
Morin and quercetin was investigated for their abilities to protect the heart from 
doxorubicin-induced damage, at the same time, without reducing the tumor killing ability of 
doxorubicin. Moreover, the cytotoxic effect of these two flavonoids alone or in combination 
with doxorubicin on HepG2 cells and doxorubicin-resistant HepG2 (R-HepG2) cells was 
studied. 
I n — stidy, viabilities of HepG2 and R-HepG2 after morin, quercetin, doxorubicin, 
or combined treatments were observed. The expressions of GST and p-glycoprotein in R-
HepG2 were also examined by SDS-PAGE electrophoresis in order to study the effect of 
morin and quercetin on multidrug resistance. 
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In vkx) study, cardioprotective and antitumor performance of combined trcatment of 
doxorubicin with morin or quercetin were investigated. Malondialdehyde (MDA) and 
thiobarbituric acid reactive substance (TBARS) contents, antioxidant capacity, glutathione-
rclated enzymes activity in heart as well as serum creatine kinase (CK) and laaate 
dehydrogenase (LDH) activity of SD rats, which had received combined treatment, were 
assayed. On the other hand, HepG2 bearing mice after receiving combined treatment were 
assayed with heart TBARS and GSH content, GSH-related enzymes, superoxide dismutase 
(SOD) activities as well as serum CK, LDH and aspartate transaminase (AST) activities. The 
tumor weights after treatment were also recorded. 
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STUDY OF CARDIOPROTECTION EFFECT OF FLAVONOIDS AGAINST 
DOXORUBICIN- INDUCED TOXICTY I N SPRAGUE-DAWLEY RATS 
2.1 Introduction 
There are many methods to investigate cardioprotective effect of antioxidants against 
doxorubicin-induced toxicity. In this chapter, an in vivo model Sprague-Dawley rat was 
applied. SD rats were treated with doxorubicin and morin or quercetin. Since free radical 
formation by doxorubicin has been shown to elevate to peak level after 10 minutes of i.v. 
perfusion in isolated rat hearts, time and dose schedules of the two flavonoids were chosen to 
be 30 minutes before i.p. injection of doxorubicin. Therefore, high levels of scavenging and 
chelating activities were met during the early stages of the presence of doxorubicin in the 
myocardium. 
To assay the level of cardiotoxicity, heart TBARS, MDA contents as well as serum 
CK and L D H activities were determined. Cardiac damage by doxorubicin is mainly due to 
lipid peroxidation. There are numerous kinds of lipid peroxide formed during lipid 
peroxidation. They are hydroperoxides, dialkjd peroxides, cyclic peroxides which m ^ 
decompose automatically into the end products alkanes, ketone, TBARS and MDA. 
Therefore, measurements of the contents of TBARS and MDA provide an indirect method 
to detect the occurrence of lipid peroxidation. Heart contains abundance of LDH and CK. 
LDH，which is a tetrameric protein, is responsible for catalyzing the interconversion of lactate 
and pyruvate. CK catalyzes the reaction between creatine phosphate and adenosine 
diphosphate, fomiing creatine and adenosine triphosphate (ATP). Serum LDH and CK 
activities are significantly elevated during cardiac dam^e. In addition to the mentioned four 
assays, glutathione (GSH)-related enzymes activities in heart were estimated in this 
experiment. Weights of SD rats were also recorded for studying the general toxicity. The 
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GSH-related enzymes being examined are glutathione peroxidase, glutathione reductase and 
glutathione transferase. They are all involved in oxidation defence system. GPx and GST are 
directly involved in detoxifying oxyradicals and organic radicals respectively. GRD 
regenerates GSH from GSSG. Therefore, examination of these three enzymes can help to 
further understand the cardioprotective mechanism of morin and quercetin. 
PicoLab Rodent Diet 20，which contains 0.2ppm selenium, was provided for the SD 
rats to avoid selenium-dependent GPx deficiency. 
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2.2 Materials and methods 
2.2.1 Materials 
2.2.1.1 Flavonoids 
Pure Morin and Quercetin powder were purchased from Sigma Chemical Company. 
They were dissolved in DMSO (Sigma, U S A ) on the day of administration and were 
protected from light until use. The concentration of Morin and Quercetin were adjusted to 
contain the required dose in 0.1 ml DMSO. 
2.2.1.2. Doxorubicin 
Doxorubicin hydrochloride was purchased from Sigma Chemical Company. It was 
reconstituted in phosphate buffer on the day of administration and was protected from light 
until use. The concentration of doxorubicin was adjusted to required dose in 0.2ml PBS. 
2.2.1.3. Animals 
Sprague-Dawley (SD) male rats (200-250g) were supplied from the Laboratory 
Animal Services Center, The Chinese University of Hong Kong. The SD rats were kept 
under the conditions of 22-25°C and a 12-hour light-dark cyde. Thq^ were fed with standaixl 
animal chow (PicoLab Rodent Diet 20，PMI Nutrition International, Inc., USA.) adlihium 
with free access to tap water. 
2.2.1.4. Chemicals 
Homogenizing buffer 
Homogenizing buffer was prepared by dissolving 6.055g Tris powder (Sigma, U S A ) 





28% trichloroacetic acid (TCA) 
28% (w/v) solution of trichloroacetic acid (BDH, England) was prepared by 
dissolving the crystal in O.IM sodium arsenite (Sigma, U.S.A.). 
0.5% thiobarbituric acid (TBA) 
O.50/0 (w/v) solution of thiobarbituric acid (Sigma, U S A ) was prepared by dissolvir^ 
the powder in 0.025M Sodium hydroxide (Sigma, U.S.A.). 
0. DmM ferric chloride 
The solution of 0.15mM ferric chloride (Merck, Germany) was prepared by dissolvii^ 
the crystal in 0.9% sodium chloride (Sigma, U.S.A.). 
MDA assays 
0.67% thiobarbituric acid fTBA) 
The 0.67% (w/v) solution of thiobarbituric acid (Sigma, USA.) was prepared by 
dissolving the powder in 1:1 acetic acid (Sigma, U.S.A.) and distilled water. 
90mM butylated hydroxytoluene 
The solution of 90mM butylated hydroxytoluene (Sigma, USA.) was prepared by 
dissolving 99.2mg crystal in 5ml isopropanol (Sigma, U.S.A.). 
4mM iron (III) chloride 
The solution of 4mM iron (III) chloride (Sigma, USA.) was prepared by dissolving 
the crystal in distilled water. 
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Basal and forced peroxidized tissue glutathione assays 
25% trichloroacetic acid 
The 25% (w/v) solution of trichloroacetic acid (BDH, England) was prepared by 
dissolving the crystal in distilled water. 
0. IMphosphate buffer (pH8.0) 
The O.IM Phosphate buffer (pH8.0) was prepared by mixing O.IM NaH2P04 (Sigma, 
U.S.A.) and O.IM NajHPO^ (Sigma, U.S.A.) to make the appropriate pH value. 
3mM 5y5-dithiobis 2-nitrobenzoic acid (DTNB) 
The solution of 3mM 5,5-clithiobis 2-nitrobenzoic acid (Sigma, U S A ) was prepared 
by dissolving 7.2mg powder of DTNB in 6ml phosphate buffer (O.IM, pH8.0). 
0,05mMt-BHP 
The solution of t-BHP (Sigma, U S A ) was prepared by adding lOul stock into 7ml 
0.9。/。NaQ to make a lOmM t-BHP first. Then 0.9% N a d was used to adjust the lOmM t-
BHP solution to the appropriate concentration. 
Glutathione reductase assays 
0A5MTris-90mMEDTA buffer (pH7.6) 
The 0.45M Tiis-90mM EDTA buffer (pH7.6) was prepared by dissolving 54.5g Tiis 
powder (Sigma, USA.) and 33.5g EDTA crystal (Sigma, U.SA) in IL distilled water. The 
buffer was then adjusted to appropriate pH value. 
18mM oxidized glutathione (GSSG) 
The solution of 18 mM oxidized glutathione (Sigma, U S A ) was prepared by 
dissolving 0.1 Ig GSSG crystals in 10ml distilled water. 
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3mM reduced nicotinamide adenine dinudeotide phosphate (NADPH) 
The solution of 3mM reduced nicotinamide adenine dinudeotide phosphate (Sigma, 
U.S.A) was prepared by dissolving lOmg NADPH crystals in 4ml distilled water. 
Glutathione transferase assays 
O.IMphosphate buffer-ImMEDTA (pH6.5) 
The O.IM Phosphate buffer-ImM EDTA (pH6.5) was prepared by dissolving 
0.3722g EDTA crystal (Sigma, U S A ) to O.IM Phosphate buffer made by mixing O.IM 
NaH^PO^ (Sigma, U.S.A.) and O.IM Na^HPO* (Sigma, U.S.A.) to make the pH value 6.5. 
20mM reduced glutathione (GSH) 
The solution of 20mM reduced glutathione was prepared by dissolving IS.Sing GSH 
crystals (Sigma, U.S.A.) in 3inl O.IM phosphate buffer-lmM EDTA (pH6.5). 
20mM l-chloro-2,4-dinitrobenzene (CDNB) 
The solution of 20mM l-chloro-2, 4-climtrobeiizene was prepared by dissolvii^ 
40mg CDNB powder (Sigma, U.S.A.) in 10ml 95% ethanol. 
Glutathione peroxidase assays 
75mMphosphate buffer (pH7.0) 
The 75mM phosphate buffer (pH7.0) was prepared by mixing O.IM NaHjPO^ 
(Sigma, U.S.A.) and O.IM NajHPO* (Sigma, U.S.A.) to make the appropriate pH value. 
Double strength dragon's solution (DSDR) 
Double strength dragon's solution was prepared by dissolving 0.1042g KCN (Sigma, 





Hydrogen peroxide solution was prepared by adding l l u l 30% hydrogen peroxide 
solution (Sigma, U.S.A.) into 13.33ml distilled water. 
SOUP 
SOUP consists of 60 mM GSH, 60 U glutathione reductase (GRD), 0.12 M NaNj, 
15mM EDTA, 3 mM NADPH and 75 mM phosphate buffer (pHZ.O). It was prepared by 
dissolving 18.5 mg GSH ciystal, 1.2 ml 50 U/ml GRD solution (Sigma, USA.), 7.8 mg NaNj 
crystals (Sigma, USA.), 11.2 g EDTA crystals and 5 mg NADPH in 46 ml 75 mM phosphate 
buffer (pH 7.0). 
Enzyme kits 
Kits of Lactate dehydrogenase (LDH) and Creatine kinase (CK) were purchased from 
Sigma (U.S.A.). 
2.2.2. Methods 
2.2.2.2. Animal studies and treatment schedules 
SD rat were randomized into experimental groups of four animals and kept in a cage. 
Group I (control): 0.1 ml DMSO was administrated i.p. twice per week. 
、Group I I (toxicity of doxorubicin)： 6 mg/kg doxorubicin was administrated i.p. 30 
minutes after 0.1ml DMSO administrated i.p., twice per week. 
Group I I I (effect of morin on myocardial toxicity of doxorubicin): 10 mg/kg morin 
was administrated i.p. 30 minutes before 6 mg/kg doxorubicin administrated i.p.，twice per 
week. 
Group IV (effect of quercetin on myocardial toxicity of doxorubicin): 10 mg/1^ 
quercetin was administrated i.p. 30 minutes before 6 mg/kg doxorubicin administrated i.p.， 
twice per week. 
A l l schedules were repeated for two weeks. 
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2.2.2.3. Evaluation of general toxicity 
The body weight of the animals was recorded twice per week for two weeks during 
the experiment as an index of general toxicity. 
2.2.2.4. Preparation of tissue samples 
Animals were anesthetized with an intraperitoneal injection of 65 mg/kg sodium 
pentobarbital on the day after the last administration of drug. Blood samples were drawn 
from hearts into heparinized syringes. Serum was then separated hy centrifugation at 1300g 
for 10 minutes and stored 4°C for 24 hours. Hearts of the rats were isolated, washed with 
homogenizing buffer, weighted and homogenized in homogenizing buffer at 13000 rpm for 
three cycles of 30 seconds on ice by the use of Polytron homogenizer to make 10% heart 
homogenate. Cytosolic fraction were obtained from diluting the homogenate to 4-fold with 
homogenizing buffer, followed by collecting the supernatant after centrifugation at 90000g 
for 30 mins. Serum samples were used for LDH and CK assays. The 10% heart 
homogenates were used for TEARS assays, MDA assays, as well as basal and forced 
peroxidized glutathione assays. Cytosolic fractions were used for gjutathione-related enzymes 
assays. 
2.2.2.5. Assays for studying cardioprotective effect 
2.2.2.5.1. L D H and CK 
L D H and CK level in serum samples were determined by use of diagnostic kit. 
2.2.2.5.2. TBARS assay 
0.4 ml 10% rat heart homogenate was mixed with 0.4 ml 0.15 mM FeClj. After 
incubation at 37°C for 30 mins, a 0.4 ml 4X： 28% TCA-arsenite was added into the reaction 
mixture to stop the reaction. The mixture was then centrifugated at 4000rpm for 10 mins. 
Then 0.8 ml of the supernatant was mixed with 0.4 ml 0.5% TBA, incubated at 90°C for 15 
mins，sonicated for 10 mins, followed by reading the absorbance at 532nm in order to 
determine TBARS level of the heart homogenate. 
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2.2.2.5.3. MDA assay 
0.5 ml 10% heart homogenate was mixed with 0.5 ml 0.67% TEA recent in 1:1 
acetic acid and distilled water, 225 ul distilled water, 25iil 90 mM BHT in isopropanol and 250 
ul 4 mM ferric chloride. The mixture was then incubated at 90。C for 30 mins. After cooling 
down the mixture to stop the reaction, 2 ml n-butanol was added and centrifuged at 3000 
ipm for 30 mins to extract MDA. The level of MDA was determined by reading the 
absorbance of the supernatant at 532 and 453 nm finally. 
2.2.2.5.4. Basal glutathione assay 
0.2 ml 10% heart homogenate, 0.1 ml 4°C 25% TCA and 0.2 ml normal saline were 
mixed and centrifuged at 1300g for 10 minutes. Then 0.2 ml supernatant was mixed with 1 
ml 0.1 M Phosphate buffer (pH8.0) and 0.05 ml 3 mM DTNB. After leaving forl5 mins at 
room temperature, the mixture was read for the absorbance at 412 nm. 
2.2.2.5.5. Forced peroxidized glutathione assay 
0.2 ml 10% heart homogenate was mixed with 0.2 ml 0.05mM t-BHP and incubated 
at 37°C for 30 min. The reaction was stopped by adding 0.1 ml 4°C 25% TCA and 
centrifuged at 1300g for 10 mins. Then 0.2 ml supernatant was mixed with 1 ml 0.1 M 
Phosphate buffer (pH8.0) and 0.05 ml 3 mM DTNB. After leaving for 15 mins at room 
temperature, the mixture was read for the absorbance at 412 nm. 
2.2.2.5.6. Glutathione reductase assay 
0.05 ml heart cytosolic fraction was mixed with 0.5 ml 0.45 M Tiis-90 mM EDTA 
(pH7.6), 0.65 ml distilled water and 0.25 ml 18 mM GSSG. Then 0.05 ml 3 mM NADPH 
was added to start the reaction. Glutathione reductase activity was determined by reading the 
absorbance of the mixture immediately at 340nm for 4 mins at 25°C. 
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2.2.2.5.7. Glutathione transferase 
20 ul cytosolic fraction was mixed with 1 ml O.IM Phosphate buffer-lmM EDTA 
(pH6.5), 50 ul 20 mM GSH and 50 ul 20 mM CDNB in 95% ethanol. Glutathione 
transferase activity was then determined by reading the absorbance of the mixture 
immediately at 340nm for 2 mins. 
2.2.2.5.8. Glutathione peroxidase assay 
0.5 ml heart cytosolic fraction and 0.5 ml DSDR were mixed and chilled at 4。C for 30 
mins. Then 0.1 ml of the mixtures were added to 1.2 ml SOUP and 0.15 ml distilled water. 
Hnally，50 ul H2O2 was added to start the reaction. Glutathione peroxidase activity was 
determined by reading the absorbance of the reaction mixture at 340nm for 4 mins. 
2.2.2.6. Statistical analysis 
The results were expressed as arithmetical mean 土 standard error. The statistical 
significance of differences was assessed by Student's Mest. The significant level was accepted 




2.3.1. General toxicity 
No deaths were observed in any experimental group during the observation period. 
As shown in Fig. 2.1，6mg/kg doxorubicin was found to impair the body weight gain 
significantly compared with control group. It could also be demonstrated that the body 
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Fig 2.1 Effect of morin and quercetin on the growth of dox-treated rats. 
oivehicle control (DMSO+sal); •： dox pMSO+6mg/l^ dox); •: mor+dox (lOmg/kg 
mor+6mg/kg dox); x: que+dox (lOmg/kg que+6mg/l^ dox) SD rats had received 
flavonoids or vehicles Lp. 30mins before i.p. administration of doxorubicin or vehicles twice 
per weeks for two weeks. Points are means of results of experiments on 5 rats at 4，8 and 12 
days, respectively. Vertical bars are S.D. 
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2.3.2. Effect of morin and quercetin on dox-induced lipid peroxidation in the heart of SD 
rat 
The levels of thiobarbituric acid (TEARS) and malondialdehyde (MDA) were 
measured to estimate the extent of lipid peroxidation in the heart after doxorubicin treatment. 
It was found in Fig. 2.2 and 2.3 that TEARS and MDA levels in heart were markedly elevated 
47% and 187% respectively by doxorubicin compared with the control group. However, 
pretreatment with lOmg/kg morin or quercetin decreased significantly the lipid peroxidation. 
Morin and quercetin reduced 38% and 57% respectively in TBARS formation. In MDA 
formation, they could reduce 187% and 200% respectively too. The level of lipid peroxides 
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Fig. 2.2 Effect of morin and quercetin on doxorubicin-induced TEARS formation in heart of 
SDrat 
Control: DMSO+sal; DMSO+dox： DMSO+6mg/kg dox； mor+dox： lOmg/kg 
mor+6mg/kg dox; que+dox: lOmg/kg que+6mg/kg dox. SD rats had received flavonoids 
or vehicles Lp. 30 mins before i.p. administration of doxorubicin or vehicles twice per week 
for two weeks. The TEARS level in hearts were measured as described in Materials and 
Methods. Each value is the average of five determinations (mean土S.D.). Vertical bars are 
the S.D. There was significant difference (p<0.05) in TEARS formation between control, 
mor+dox, que+dox and DMSO+dox groups. 
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Fig. 2.3. Effect of morin and quercetin on doxombicin-induced MDA formation in heart of 
SD rat 
Control: DMSO+sal； DMSO+dox： DMSO+6mg/kg dox； mor+dox： lOmg/kg 
mor+6mg/l^ dox; que+dox: lOmg/kg que+6mg/kg dox. SD rats had received flavonoids 
or vehicles i.p. 30 mins before i.p. administration of doxorubicin or vehicles twice per week 
for two weeks. The MDA levels in hearts were measured as described in Materials and 
Methods. Each value is the average of five determinations (mean土S.D.). Vertical bars are 
the S.D. There was significant difference (p<0.05) in MDA formation between control， 
mor+dox, que+dox and DMSO+dox groups. 
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2.3.3. Effect of morin and quercetin on the activities of gjutathione-related enzyme in the 
heart of dox-treated SD rat 
Heart glutathione peroxidase (GPx) and glutathione reductase (GRD) activities were 
significantly elevated after the doxorubicin-alone treatment (P<0.05) (Fig. 2.4 and 2.5). Their 
activities of GPx and GRD were 401mU/mg and 82mU/mg respectively compared with 
314mU and 19mU in the heart of the rats in control group. However, pretreatment with 
lOmg/k^ morin or quercetin decreased significantly the activities back to the levels as the 
control group. In the assay of glutathione peroxidase, it was found that morin and quercetin 
could reduce the elevated GPx activity to 322mU/mg and 318mU/mg respectively in dox-
alone-treated SD rats. In glutathione reductase activity determination, it was also found that 
these two flavonoids reduced the elevated heart GRD activity to 18mU/mg and 12mU/mg. 
There was no significant difference of both enzyme activities among the groups of control, 
morin with dox and quercetin with dox. 
However, the flavonoid pre-treatment with lOmg/kg morin or quercetin could not 
reduce the doxorubicin-elevated glutathione-S-transferase activity (Fig. 2.6). It was found 
that doxorubicin increased the GST activity from 150uU/mg as in the control group to 
185mU/mg. In the groups pre-treated with morin and quercetin, the heart GST activities 
were 165mU/mg and 175mU/mg respectively. There was a trend of increased GST activity 
by doxorubicin, which could not be improved by morin and quercetin, though the findings 
were not significant. 
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Fig. 2.4 Effect of morin and quercetin on glutathione peroxidase activities in the hearts of 
dox-treated SD rats 
Control: DMSO+sal； DMSO+dox： DMSO+6mg/kg dox； mor+dox： lOmg/kg 
mor+6mg/kg dox; que+dox: lOmg/kg que+6mg/kg dox. SD rats had received flavonoids 
or vehicles i.p. 30 mins before i.p. administration of doxorubicin or vehicles twice per week 
for two weeks. The activities of GPx in hearts were determined as described in Materials and 
Methods. Each value is the average of five determinations (mean土S.D.). Vertical bars are 
the S.D. There was significant difference (p<0.05) in glutathione peroxidase activities 
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Fig. 2.5. Effect of morin and quercetin on glutathione reductase activities in the hearts of 
dox-treated SD rats 
Control: DMSO+sal; DMSO+dox： DMSO+6mg/kg dox； mor+dox: lOmg/kg 
mor+6mg/kg dox; que+dox: lOmg/kg que+6mg/kg dox. SD rats had received flavonoids 
or vehicles i.p. 30 mins before i.p. administration of doxorubicin twice per week for two 
weeks. The activities of GRD in hearts were determined as described in Materials and 
Methods. Each value is the average of five determinations (mean士S.D.). Vertical bars are the 
S.D. There was significant difference (p<0.05) in glutathione reductase activities between 
control, mor+dox, que+dox and DMSO+dox groups. 
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Fig. 2.6. Effect of morin and quercetin on gJutathione-S-transferase activities in the hearts of 
dox-treated SD rats 
Control: DMSO+sal; DMSO+dox： DMSO+6mg/kg dox; mor+dox： lOmg/kg 
mor+6mg/kg dox; que+dox: lOmg/kg que+6mg/kg dox. SD rats had received flavonoids 
or vehicles i.p. 30 mins before i.p. administration of doxorubicin or vehicles twice per week 
for two weeks. The activities of GST in hearts were determined as described in Materials and 
Methods. Each value is the average of five determinations (mean土S.D.). Vertical bars are 
the S.D. There was no significant difference in glutathione-S-transferase activities among 
control, mor+dox, que+dox and DMSO + dox groups. 
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2.3.4. Effect of morin and quercetin on dox-induced creatine kinase and lactate 
dehydrogenase release from the hearts of SD rats 
Sera from the experimental SD rats for determination of lipid peroxidation were 
collected for the creatine kinase (CK) and lactate dehydrogenase (LDH) measurement. As 
shown in Fig. 2.7，doxorubicin significantly increased serum CK level to 492 U /L in dox-
alone-treated SD rats. Pre-treatment with lOmg/kg morin or quercetin completely inhibited 
the increase in the serum CK level (p<0.05). The serum CK level in morin and quercetin 
treated SD rats were 293U/L and 285U/L respectively. They were similar to the level in 
control group (277U/L). 
The level of serum LDH was 1483U/L in control SD rats and 4153U/L in dox-
treated group (Fig. 2.8). It demonstrated that doxorubicin could significantly increase serum 
LDH level in SD rats (p<0.05). However, it was also found that pre-treatment with lOmg/kg 
morin and quercetin could effectively inhibit such dam^e in dox-treated SD rats. The level 
of serum LDH in morin co-treated and quercetin co-treated groups werc 1572U/L and 
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Fig. 2.7 Effect of morin and quercetin dox-induced creatine kinase release from the hearts 
of SD rats 
Control: DMSO+sal; DMSO+dox: DMSO+6mg/kg dox; mor+dox: lOmg/1^ 
mor+6mg/kg dox; que+dox： lOmg/kg que+6mg/kg dox. SD rats had received flavonoids 
or vehicles i.p. 30 mins before i.p. administration of doxorubicin or vehicles twice per week 
for two weeks. The activities of CK in serum were determined as described in Materials and 
Methods. Each value is the average of five determinations (mean土S.D.). Vertical bars are 
the S.D. There was significant difference in Creatin kinase release between control, 
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Fig. 2.8 Effect of morin and quercetin on dox-induced lactate dehydrogenase release from 
the hearts of SD rats 
Control: DMSO+sal; DMSO+dox： DMSO+6mg/kg dox； mor+dox: lOmg/kg 
mor+6mg/kg dox; que+dox： lOmg/kg que+6mg/kg dox. SD rats had received flavonoids 
or vehicles i.p. 30 mins before i.p. administration of doxorubicin or vehicles twice per week 
for two weeks. The activities of LDH in serum were determined as described in Materials 
and Methods. Each value is the average of five determinations (mean土S.D.). Vertical bars 
are the S.D. There was significant difference in Lactate dehydrogenase release between 
control，mor+dox, que+dox and DMSO + dox groups (p<0.05). 
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2.4.5. Effect of morin and quercetin on antioxidative capacity in the hearts of dox-treated 
SD rats 
This was an assay to study the antioxidative capacity of the hearts of SD rats after 
doxorubicin treatment. It was reflected by the percentage of glutathione depletion after an 
oxidative challenge (Fig. 2.9). The heart homogenate of the control after the challenge 
exhibited 15.7% glutathione depletion while the dox-alone-treated SD rats showed 24.9%. 
However, pre-treatment with lOmg/kg morin and quercetin to the SD rats before 
doxorubicin administration could reduce the percentage of GSH depletion to 10.7% and 
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Fig. 2.9 Effect of morin and quercetin on the antioxidative capacity in the hearts of dox-
treated SD rats 
Control: DMSO+sal; DMSO+dox： DMSO+6mg/kg dox； mor+dox： lOmg/kg 
mor+6mg/kg dox; que+dox: lOmg/kg que+6mg/kg dox. SD rats had received flavonoids 
or vehicles i.p. 30 mins before i.p. administration of doxorubicin or vehicles twice per week 
for two weeks. The GSH contents in hearts were measured as described in Materials and 
Methods. Each value is the average of five determinations (mean土S.D.). Vertical bars are 
the S.D. There was significant difference in % of heart glutathione depletion between 
control, mor+dox, que+dox and DMSO+dox groups (p <0.05). 
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2.4. Discussion 
Doxorubicin-related reactive oxygen metabolism overwhelms the limited capacity of 
cardiac muscle to detoxify free radicals, resulting in extensive peroxidative damage to 
myocardial cells. The two antioxidant flavonoids morin and quercetin which are 
polyphenolic compounds found in fruits and vegetables are expected to trap such reactive 
oxygen species and harmless to the host. In present study, it was demonstrated that 
treatment of experimental animals with lOmg/kg of morin and quercetin rescued the heart. 
The levels of lipid peroxidation products, TBARS and MDA, in the heart of experimental 
animals treated with morin or quercetin and doxorubicin were similar to the levels in the 
control SD rats. It indicated that doxorubicin introduced in these two groups did not cause 
any further lipid peroxidation in their hearts. The oxyradicals produced by doxorubicin might 
be scavenged by morin and quercetin, and thus no radicals attack the myocardial cells. 
Moreover, the serum CK and LDH activities were also found to be similar with the control 
one, while it was 80% more active in dox-control group. 
The hearts of the test-group seemed have no damage by doxorubicin. Morin and 
quercetin reserved the antioxidant capacity of the heart also. After oxidation challenge, only 
11% of the heart GSH depleted, while there was 25% of GSH depletion in dox-control 
group. These results can be explained by two reasons. First, morin and quercetin had 
scavenged the oxyradicals generated by doxorubicin after administration, so that the 
consumption of GSH reduced. There was still quite much amount of GSH in the pool to 
encounter the oxidation challenge later. Second, the morin and quercetin remained in the 
heart and were used to encounter the oxidation challenge. Therefore GSH in the pool was 
preserved. 
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The activities of GRD and GPx in the heart of the two test-groups were found to be 
similar with control SD rats as expected. It has been widely believed that flavonoids exhibit 
antioxidant effect by radical scavenging ability. The activities of these two enzymes would 
not be induced. The other reason is that the consumption of GSH reduced in the presence 
of morin and quercetin. GRD and GPx activities would not been induced since less substrate 
existed. However, they were largely elevated in dox-control group. The oxyradicals 
produced by doxorubicin induced the activity of GPx to detoxify them. Therefore, the 
consumption of GSH increased and GRD activity increased to regenerate GSH from GSSG 
for more detoxification reactions. 
The activities of GST had no significant difference among all groups of SD rats, 
including the normal control one though the activities at this group was slightly lower. The 
role of GST in biological systems is to catalyze the conjugation of GSH with organic 
peroxides. However, the radicals generated in doxorubicin metabolism are mainly oxyradicals, 
on which GST has no effect. Therefore, only insignificant elevations on the GST activities 
were found. 
In addition to studying the effect and mechanism on cardioproteaion, the general 
protective effect of morin and quercetin against doxombicin-induced damages was studied 
The schedule adopted in the present study for doxorubicin administration of 6mg/kg twice a 
week for two weeks in SD rat produced a general toxic sign evidenced by a significant 
impairment of body we缺t gain. Although morin and quercetin significantly protected the 
heart from doxorubicin damage, they exhibited no effect on general protection. Tissues 
other than heart may be damaged by doxorubicin by a mechanism not involve radicals. Apart 
fmm generating oxyradicals, doxorubicin can kill cells by intercalation of DNA as well as 
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inhibiting topoisomerase 11. The later one can kill highly proliferative cells in liver and 
intestine. 
Further investigation have to be done in order to examine whether the two 
flavonoids, morin and quercetin, can give not only cardioprotective, but also general 
protective effect against doxorubicin damage. 
. 53 
Chapters 
STUDY OF EFFECT OF FLAVONOIDS I N CHEMOTHERAPY OF 
DOXORUBICIN I N TUMOR-BEARING MICE 
3.1 Introduction 
Athymic babl/c mice (nude mice) were used to study the effect of morin and 
quercetin on doxorubicin induced cardiotoxicity and antitumor activity. Thymus function of 
the nude mice had been impaired, and thus they had no immune system to act against the 
inoculation of human hepatoma (HepG2) cells. The elimination of the inoculated tumor 
found in our experiments was mainly due to the chemotherapy. However, because of no 
immune system, the nude mice had to be kept under sterile conditions. They were kept in 
autoclaved cages with filter bonnet and fed with autoclaved PicoLab Rodent Diet 20 and 
water, otherwise, they would died from infection. 
Flavonoids were administrated orally to avoid damages caused by i.p. injection and to 
maximize the absorption of morin and quercetin by the nude mice. Doxorubicin was 
injected i.v. to reduce the amount of doxorubicin administrated which cause adverse side 
effect dose-dependently to the mice. Sequence of drug admimstration was same as the 
previous chapter that morin and quercetin were forced fed 30 minutes before i.v. injection of 
doxorubicin. Therefore, high levels of scavenging and chelating activities were expected to 
be met during the early stages of the presence of doxorubicin in the myocardium. 
Apart form assays of heart TBARS content, glutathione-related enzymes activities as 
well as serum CK and LDH activities, assays of heart GSH content and superoxide dismutase 
activity were done. Glutathione is an endogenous nonenzymatic antioxidant in biological 
system. Its level will be depleted in the presence of oxidant. Superoxide dismutase is an 
endogenous enzymatic antioxidant. Its activity may be changed when encountering oxidative 
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challenges. Examinations of them facilitated the evaluation of cardioprotective effect and 
understanding its mechanism. Moreover, the serum aspartate transaminase (AST) activity 
was studied to determine the heart and general damage in other tissue after combined 
treatment. AST is abundance in cells of heart. Elevated serum activity of AST may indicate 
heart damages. Finally, tumor weights were recorded to demonstrate whether the antitumor 
ability of doxorubicin was affected by the morin and quercetin. 
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3.2, Materials and methods 
3.2.1 Materials 
3.2.1.1 Flavonoids 
Pure Morin and Quercetin powder were purchased from Sigma Chemical Company. 
They were dissolved in PBS on the day of administration and were protected from light until 
use. The concentration of Morin and Quercetin were adjusted to contain the required dose 
in 0.2 ml PBS. 
3.2.1.2. Doxorubicin 
Doxorubicin hydrochloride was purchased from Sigma Chemical Company. It was 
reconstituted in phosphate buffer on the day of administration and was protected from light 
until use. The concentration of doxorubicin was adjusted to required dose in 0.2ml PBS. 
3.2.1.3. Animals 
Male athymic nude Balb/c mice (6-8 week) were supplied from the Laboratory 
Animal Services Center, The Chinese University of Hong Kong. The mice were kept under 
the sterile conditions in autoclaved cages with filter bonnets ml2-25X^ and 12-hour light-dark 
cycle. They were fed with sterile standard animal chow (PicoLab Rcxlent Diet 20, PMI 
Nutrition International, Inc., U.S.A.) ad libitum with sterile water. 
3.2.1.4. Chemicals 
Homogenizing buffer 
Homogenizing buffer was prepared by dissolving 6.055g Tris powder (Sigma, U.SA) 




28% trichloroacetic acid fTCA) 
The 28% (w/v) solution of trichloroacetic acid (BDH, England) was prepared by 
dissolving the crystal in O.IM sodium arsenite (Sigma, U.S.A.). 
0.5% thiobarbituric acid (TBA) 
The 0.5% (w/v) solution of thiobarbituric acid (Sigma, U.SA) was prepared by 
dissolving the powder in 0.025M Sodium hydroxide (Sigma, U.S.A.). 
0.15mM ferric chloride 
The solution of 0.15mM ferric chloride (Merck, Germany) was prepared by dissolving 
the crystal in 0.9% sodium chloride (Sigma, U.S.A.). 
Basal and forced peroxidized tissue glutathione assays 
25% trichloroacetic acid 
The 25% (w/v) solution of trichloroacetic acid (BDH, England) was prepared by 
dissolving the crystal in distilled water. 
0. IM phosphate buffer (pH8.0) 
The O.IM phosphate buffer (pH8.0) was prepared by mixing O.IM NaH2P04 (Sigma, 
U.S.A.) and O.IM NaaHPO* (Sigma, U.S.A.) to make the appropriate pH value. 
3mM 5,5-dithiobis 2-nitrobenzoic acid (DTNB) 
The solution of 3inM 5,5-clithiobis 2-nitrobenzoic acid (Sigma, U.SA) was prepared 
by dissolving 7.2mg powder of DTNB in 6ml Phosphate buffer (O.IM, pH8.0). 
0.05mMt-BHP 
The solution of t-BHP (Sigma, U.SA) was prepared by adding lOul stock into 7ml 
0.9% NaCl to make a lOmM t-BHP first. 0.9% NaCl was then used to adjust the lOmM t-
BHP solution to the appropriate concentration. 
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Glutathione reductase assays 
0A5M Tris-90mMEDTA buffer (pH7.6) 
The 0.45M Tris-90mM EDTA buffer (pH7.6) was prepared by dissolving 54.5g Tris 
powder (Sigma, U.SA.) and 33.5g EDTA crystal (Sigma, U.SA) in IL distilled water. The 
buffer was then adjusted to appropriate pH value. 
18mM oxidized Glutathione (GSSG) 
The solution of 18 mM oxidized Glutathione (Sigma, U.SA) was prepared by 
dissolving 0.1 Ig GSSG crystals in 10ml distilled water. 
3mM reduced nicotinamide adenine dinucleotide phosphate (NADPH) 
The solution of 3mM reduced nicotinamide adenine dinucleotide phosphate (Sigma, 
U.S.A) was prepared by dissolving lOmg NADPH crystals in 4ml distilled water. 
Glutathione transferase assays 
O.IMphosphate buffer-lmMEDTA (pH6.5) 
O.IM Phosphate buffer-lmM EDTA (pH6.5) was prepared by dissolving 0.3722g 
EDTA crystal (Sigma, U.S.A.) to O.IM Phosphate buffer made by mixing O.IM NaHjPO* 
(Sigma, U.S.A.) and O.IM NaaHPC^ (Sigma, U.S.A.) to make the pH value 6.5. 
20mM reduced glutathione (GSH) 
The solution of 20mM reduced glutathione was prepared by dissolving 18.5n^ GSH 
crystals (Sigma, U.S.A.) in 3ml O.IM Phosphate buffer-lmM EDTA (pH6.5). 
20mM l-chloro-2y4-dinitrobenzene (CDNB) 
The solution of 20mM l-chloro-2, 4-dinitrobeiizene was prepared by dissolving 
40mg CDNB powder (Sigma, U.S.A.) in 10ml 95% ethanol. 
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Glutathione peroxidase assays 
75mMphosphate buffer (pH7.0) 
The 75niM phosphate buffer (pH7.0) was prepared by mixing O.IM NaHyPO* 
(Sigma, U.S.A.) and O.IM Na2HP04 (Sigma, U.S.A.) to make the appropriate pH value. 
Double strength dragon's solution (DSDR) 
Double strength dragon's solution was prepared by dissolving 0.1042g KCN (Sigma, 
USA.), 0.51g K3Fe(CN)6 (Sigma, USA.) and 2g NaHCX), (Sigma, USA.) in IL distilled 
water. 
Hydrogen peroxide 
Hy^drogen peroxide solution was prepared by adding l l u l 30% hydrogen peroxide 
solution (Sigma, U.S.A.) into 13.33ml distilled water. 
SOUP 
SOUP consists of 60 mM GSH, 60 U glutathione reductase (GRD), 0.12 M NaNj, 
15mM EDTA, 3 mM NADPH and 75 mM Phosphate buffer (pH7.0). It was prepared by 
dissolving 18.5 mg GSH crystal, 1.2 ml 50 U/ml GRD solution (Sigma, U.SA.), 7.8 mg NaNj 
crystals (Sigma, U.S.A.)，11.2 g EDTA crystals and 5 mg NADPH in 46 ml 75 mM Phosphate 
buffer (pH 7.0). 
Enzyme kits 
Kits of laaate dehydrogenase (LDH), creatine kinase (CK), and aspartate 
transaminase (AST) were purchased from Sigma (U.S.A.). 
Kit of Superoxide dismutase (SOD) was purchased from Calbiochem (Germany). 
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3.2.1.5. Tumor cell 
Cell line human hepatoma (HepG2) was obtained from ATOC. Cells were 
trypsinized and resuspended in PBS to a concentration of 2X10^ cells/ml. 
3.2.2. Methods 
3.2.2.2. Innoculation of HepG2 into nude balb/c mice 
4X106 HepG2 were injected subcutaneously into the nude mices. The mice were 
than randomized into experimental groups of five and kept in a cage. 
3.2.2.3. Animal studies and treatment schedules 
Group I (no tumor/control): 0.2 ml phosphate buffer was force fed and 
administrated i.v. respectively. 
Group I I (HepG2/control): 0.2 ml phosphate buffer was forced fed and 
administrated i.v. respectively. 
Group m (HepG2/toxicity of doxorubicin): 2 mg/kg doxorubicin was administrated 
i.v. 30 minutes after 0.2ml PBS force-fed. 
Group IV (HepG2/effea of morin on myocardial toxicity of doxorubicin)： 2 mg/kg 
morin was force fed 30 minutes before 2 mg/kg doxorubicin administrated i.v. 
Group V (HepG2/effea of quercetin on myocardial toxicity of doxorubicin): 2 
mg/kg quercetin was force fed 30 minutes before 2 mg/kg doxorubicin administrated i.v. 
M schedules were repeated three times per week for three week starting from the day 
after tumor inoculation. 
3.2.2.4. Preparation of tissue samples 
Animals were anesthetized with an intraperitoneal injection of 65 mg/k^ sodium 
pentobarbital on the day after the last administration of drug. Blood samples were drawn 
from hearts into heparinized syringes. Serum was then separated by centrifugation at 1300g 
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for 10 minutes and stored 4。C for 24 hours. Hearts of the rats were isolated, washed with 
homogenizing buffer, weighted and homogenized in homogenizing buffer at 13000 rpm for 
three cycles of 30 seconds on ice by the use of Polytron homogenizer to make 10% heart 
homogenate. Cytosolic fraction were obtained from diluting the homogenate to 4-fold with 
homogenizing buffer, followed by collecting the supernatant after centiifugation at 90000g 
for 30 mins. Serum samples were used for lactate dehydrogenase (LDH)，creatine kinase 
(CK) and aspartate transaminase (AST) assays. Then 10% heart homogenates were used for 
TBARS assays, MDA assays, as well as basal and forced peroxidized glutathione assays. 
Cytosolic fractions were used for glutathione-related enzymes assays. 
3.2.2.5. Assays for studying cardioprotective effect 
3.2.2.5.1. LDH, CK and AST 
LDH, CK and AST level in serum samples and SOD level in 10% heart homogenate 
were determined by use of diagnostic kits. 
3.2.2.5.2. TBARS assay 
0.4 ml 10% rat heart homogenate was mixed with 0.4 ml 0.15 mM FeQy After 
incubation at 37°C for 30 mins, 40.4 ml iX： 28% TCA-arsenite was added into the reaction 
mixture to stop the reaction. The mixture was then centrifugated at 4000 rpm for 10 mins. 
Then 0.8 ml of the supernatant was mixed with 0.4 ml 0.5% TBA, incubated at for 15 
mins, sonicated for 10 mins, followed by reading the absorbance at 532iim in order to 
determine TBARS level of the heart homogenate. 
3.2.2.5.3. Basal glutathione assay 
0.2 ml 10% heart homogenate, 0.1 ml 4。C 25% TCA and 0.2 ml normal saline were 
mixed and centiifuged at 1300g for 10 minutes. Then 0.2 ml supernatant was mixed with 1 
ml 0.1 M phosphate buffer (pH8.0) and 0.05 ml 3 mM DTNB. After leaving forl5 mins at 
room temperature, the mixture was read for the absorbance at 412 nm. 
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3.2.2.5.4. Forced peroxidized glutathione assay 
0.2 ml 10% heart homogenate was mixed with 0.2 ml 0.05mM t-BHP and incubated 
at 37。C for 30 min. The reaction was stopped by adding 0.1 ml 4冗 25% TCA and 
centrifuged at 1300g for 10 mins. Then 0.2 ml supernatant was mixed with 1 ml 0.1 M 
Phosphate buffer (pH8.0) and 0.05 ml 3 mM DTNB. After leaving forl5 mins at room 
temperature, the mixture was read for the absorbance at 412 nm. 
3.2.2.5.5. Glutathione reductase assay 
0.05 ml heart cytosolic fraction was mixed with 0.5 ml 0.45 M Tiis-90 mM EDTA 
(pH7.6), 0.65 ml distilled water and 0.25 ml 18 mM GSSG. Then 0.05 ml 3 mM NADPH 
was added to start the reaction. Glutathione reductase activity was determined by reading the 
absorbance of the mixture immediately at 340nm for 4 mins at 25°C. 
3.2.2.5.6. Glutathione transferase 
20 ul cytosolic fraction was mixed with 1 ml O.IM phosphate buffer-ImM EDTA 
(pH6.5), 50 ul 20 mM GSH and 50 ul 20 mM CDNB in 95% ethanol. Glutathione 
transferase activity was then determined by reading the absorbance of the mixture 
immediately at 340nm for 2 mins. 
3.2.2.5.7. Glutathione peroxidase assay 
0.5 ml heart cytosolic fraction and 0.5 ml DSDR were mixed and chilled at 4°C for 30 
mins. Then 0.1 ml of the mixture were added to 1.2 ml SOUP and 0.15 ml distilled water. 
Finally, 50 ul H2O2 was added to start the reaction. Glutathione peroxidase activity was 
determined by reading the absorbance of the reaction mixture at 340nm for 4 mins. 
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3.3. Results 
3.3.1. Effect of morin and quercetin on the anti-tumor activity of doxorubicin in HepG2-
bearing nude mice 
After HepG2 inoculations, the mice were given chemotherapy for 3 weeks. In four 
groups of tumor bearing mice, the tumor control group, which received no treatment, was 
found to bear an average of 0.02684g tumors (Fig. 3.1.). However, in the groups of 
doxorubicin-alone treatment, the mice were bearing only 0.00308g tumors on average. The 
tumors were lai^ely eliminated. The co-treatment of flavonoids and doxorubicin gave a 
better performance. The tumors on mice receiving morin or quercetin pre-treatment were 
oiJy 0.00132g and O.OOOlSg respectively. The reduction of tumor weight by doxorubicin and 
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Fig. 3.1. Effect of morin and quercetin on the anti-tumor activity of doxorubicin in HepG2-
bearing nude mice 
Chemotherapy was given to the HepG2-bearing nude mice for three weeks after the day of 
tumor cell inoculation. The mice had received flavonoids or vehicles orally 30 mins before 
i.v. administration of doxorubicin or vehicles three times per week. Tumor weights were 
recorded at the day of scarifications. Tumor control： PBS+PBS; PBS+dox：： PBS+2mg/kg 
dox; mor+dox: 2mg/kg mor+2mg/kg dox; que+dox: 2mg/kg que+2mg/kg dox Each 
value is the average of five determinations (mean土S.D.). Vertical bars are the S.D. There 
was significant difference in tumor weight between PBS+dox, mor+dox, que+dox and 
tumor control groups (p < 0.05). 
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3.3.2. Effect of morin and quercetin on heart lipid peroxidation of HepG2-beaimg nude 
mice receiving doxorubicin chemotherapy 
The levels of thiobarbituric acid (TBARS) were measured to estimate the extent of 
lipid peroxidation in the heart after doxorubicin chemotherapy. It was found that TBARS 
levels in heart were elevated 20.7% in tumor control group (Fig. 3.2.). When mice received 
doxombicin-alone treatment, their heart TBARS levels increased 71.9% significantly 
(p<0.05). However, pretreatment with 2mg/kg morin or quercetin decreased significantly 
the lipid peroxidation (p <0.05). In the group of morin and doxorubicin co-treatment, there 
was only 11.7% elevation of TBARS formation compared with the normal control group, 
which had no tumor and received vehicle only. The admimstration of quercetin could even 
reduce 10% TBARS formation than the normal control group. The level of TBARS in these 
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Fig. 3.2. Effect of morin and quercetin on heart lipid peroxidation of HepG2-bearing nude 
mice receiving doxorubicin chemotherapy 
Chemotherapy was given to the HepG2-bearing nude mice for three weeks after the day of 
tumor cell inoculation. The mice had received flavonoids or vehicles orally 30 mins before 
i-v. administration of doxorubicin or vehicles three times per week Normal control (no 
tumor): PBS+PBS; tumor control: PBS+PBS; PBS+dox： PBS+2mg/kg dox; mor+dox： 
2mg/kg mor+2ii^/kg dox; que+dox: 2mg/kg que+2mg/kg dox. The TBARS contents in 
hearts were measured as described in Materials and Methods. Each value is the average of 
five detemiinations (mean土S.D.). Vertical bars are the S.D. There was significant difference 
(p<0.05) in TBARS formation between normal control, tumor control, mor+dox, que+dox 
and PBS + dox groups. 
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3.4.3. Effect of morin and quercetin on heart glutathione level in HepG2-bearing nude 
mice receiving doxorubicin chemotherapy 
Normal control mice and tumor control mice exhibited a similar level of heart 
glutathione level, which were 5.05mnol/mg and 5.76nmol/mg (Fig. 3.3.). However, when 
tumor-bearing mice received doxorubicin treatment, they were found to have a significantly 
lower glutathione level in heart (p<0.05). The mice which received dox-alone treatment had 
the lowest level of glutathione, 4.15ninol/mg. Pre-treatment with 2mg/l^ morin and 
quercetin improve the consumption of GSH although the later was not significant. The GSH 
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Fig. 3.3. Effect of morin and quercetin on heart glutathione level in HepG2-bearing nude 
mice receiving doxorubicin chemotherapy 
Chemotherapy was given to the HepG2-bearing nude mice for three weeks after the day of 
tumor cell inoculation. The mice had received flavonoids or vehicles orally 30 mins before 
i.v. administration of doxorubicin or vehicles three times per week. Normal control (no 
tumor): PBS+PBS; tumor control: PBS+PBS； PBS+dox： PBS+2mg/kg dox； mor+dox: 
2mg/kg mor+2mg/kg dox; que+dox: 2mg/k^ que+2mg/k^ dox. The GSH contents in 
hearts were measured as described in Materials and Methods. Each value is the average of 
five determinations (mean+S.D.). Vertical bars are the S.D. There was significant difference 
(p<0.05) in heart glutathione level between normal control, tumor control, mor+dox and 
PBS+dox groups. 
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3.4.4. Effect of morin and quercetin on glutathione-related enzymes in the heart of HepG2-
bearing nude mice receiving doxorubicin chemotherapy 
3.4.4.1. Glutathione peroxidase 
The activity of heart glutathione peroxidase in normal control group and tumor 
control group were 97mU/mg and 115.8mU/mg respectively (Fig. 3.4.). After doxombicin-
only treatment, the tumor-bearing mice were found to have an elevated GPx activity, 
267.9mU/mg. However, the introduction of morin and quercetin pre-treatment could reduce 
the GPx activities to 161.8mU/mg and 127.8mU/mg respectively. The reduction of GPx 
activity by morin and quercetin was found to be significant (p < 0.05). 
3.4.4.2. Glutathione reductase 
Doxorubicin elevated the GRD activity significantly (p<0.05) in tumor-bearing mice 
during the chemotherapy. It was found that the mice received doxorubicin only exhibited 
531.1mU/mg GRD activity, while normal control group and tumor control group exhibited 
171.3mU/mg and 191.2mU/mg respectively (Fig. 3.5.). In the two groups of co-treatment, 
morin and quercetin could significantly reduce the GRD activity (p<0.05). They showed 
286.1mU/mg and 319.7mU/mg respectively. 
3.4.4.3. Glutathione-S-transferase 
Tumor control group was found to have a higher activity of GST than that of 
normal control group. They were 612.6mU/mg and 519.9mU/n^ respectively. In the group 
of tumor-bearing mice receiving doxorubicin treatment, they exhibited a significant increase 
of GST activity (p<0.05), 744.8mU/mg (Fig. 3.6.). Similar as the results mentioned above, 
morin and quercetin significantly reduced the GST activity in tumor-bearing mice receiving 
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Fig. 3.4. Effect of morin and quercetin on glutathione peroxidase in the heart of HepG2-
bearing nude mice receiving doxorubicin chemotherapy 
Chemotherapy was given to the HepG2-bearmg nude mice for three weeks after the day of 
tumor cell inoculation. The mice had received flavonoids or vehicles orally 30 mins before 
i-v. administration of doxorubicin or vehicles three times per week. Normal control (no 
tumor): PBS+PBS; tumor control: PBS+PBS; PBS+dox: PBS+2mg/kg dox; mor+dox： 
2mg/kg mor+2mg/kg dox; que+dox: 2mg/kg que+2mg/kg dox. The activities of GPx in 
hearts were determined as described in Materials and Methods. Each value is the average of 
five determinations (mean丄S.D.). Vertical bars are the S.D. There was significant difference 
(p<0.05) in glutathione peroxidase activity between normal control, tumor control, mor+dox, 
que+dox and PBS + dox groups. 
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Fig. 3.5. Effect of morin and quercetin on glutathione reductase in the heart of HepG2-
bearing nude mice receiving doxorubicin chemotherapy 
Chemotherapy was given to the HepG2-bearmg nude mice for three weeks after the day of 
tumor cell inoculation. The mice had received flavonoids or vehicles orally 30 mins before 
i-v. admimstration of doxorubicin or vehicles three times per week. Normal control (no 
tumor): PBS+PBS; tumor control: PBS+PBS; PBS+dox: PBS+2mg/kg dox； mor+dox: 
2mg/kg mor+2mg/kg dox; que+dox： 2mg/kg que+2mg/kg dox. The activities of GRD in 
hearts were determined as described in Materials and Methods. Each value is the average of 
five determinations (mean±S.D.). Vertical bars are the S.D. There was significant difference 
(p<0.05) in glutathione reductase activity between normal control, tumor control, mor+dox, 
que+dox and PBS + dox groups. 
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Fig. 3.6. Effect of morin and quercetin on glutathione transferase in the heart of HepG2_ 
bearing nude mice receiving doxorubicin chemotherapy 
Chemotherapy was given to the HepG2-bearing nude mice for three weeks after the day of 
tumor cell inoculation. The mice had received flavonoids or vehicles orally 30 mins before 
i-v. administration of doxorubicin or vehicles three times per week Normal control (no 
tumor): PBS+PBS; tumor control: PBS+PBS; PBS+dox: PBS+2mg/kg dox; mor+dox: 
2mg/kg mor+2mg/kg dox； que+dox： 2mg/kg que+2ing/kg dox. The activities of GST in 
hearts were determined as described in Materials and Methods. Each value is the averse of 
five determinations (mean土S.D.). Vertical bars are the S.D. There was significant difference 
(p<0.05) 
in glutathione-S-transferase activity between normal control, tumor control 
mor+dox, que+dox and PBS+dox groups. 
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3.4.5. Effect of morin and quercetin on heart Superoxide dismutase activity in HepG2-
bearing nude mice receiving doxorubicin chemotherapy 
Normal control group and tumor control group showed similar heart superoxide 
dismutase activities, which were 5.5U/mg and 6.8U/mg respectively. Tumor-bearing mice 
having doxorubicin treatment only were found to have a significant increase in the activity 
(p<0.05), and exhibited 14.6U/mg as shown in Fig. 3.7. However, pre-treatment with 
2mg/kg morin or quercetin demonstrated a reduction of the elevated activity to control 
group levels significantly (p<0.05). They exhibited the activities of 4.8U/mg and 5.1U/mg 
respectively, which were even lower than that of the control groups. 
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Fig. 3.7. Effect of morin and quercetin on superoxide dismutase activity in the heart of 
HepG2-bearing nude mice receiving doxorubicin chemotherapy 
Chemotherapy was given to the HepG2-bearing nude mice for three weeks after the day of 
tumor cell inoculation. The mice had received flavonoids or vehicles orally 30 mins before 
i.v. administration of doxorubicin or vehicles three times per week. Normal control (no 
tumor): PBS+PBS; tumor control: PBS+PBS; PBS+dox: PBS+2mg/kg dox； mor+dox: 
2mg/kg mor+2ing/kg dox; que+dox: 2mg/kg que+2mg/kg dox. The activities of SOD in 
hearts were determined as described in Materials and Methods. Each value is the average of 
five determinations (mean土S.D.). Vertical bars are the S.D. There was significant difference 
(p<0.05) in superoxide dismutase activity between normal contral, tumor control, mor+dox, 
que+dox and PBS+dox groups. 
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3.4.6. Effect of morin and quercetin on the release of creatine kinase and lactate 
dehydrogenase in HepG2-bearing nude mice receiving doxorubicin chemotherapy 
Doxorubicin chemotherapy significantly raised the creatine kinase release in tumor-
bearing mice, no matter co-treated with morin and quercetin (p<0.05). The serum CK 
activities in normal control and tumor control groups were only 621.4U/L and 674.5U/L 
respectively, while they were 1269U/L, 1114U/L and 1013.3U/L respectively in dox-alone 
treated group, morin-co-treated group and quercetin-co-treated group (Fig. 3.8.). 
However, it was found that pre-treatment with morin and quercetin could reduce the 
increased LDH release by doxorubicin. Doxorubicin significantly elevated the serum LDH 
activity from 229.1U/L as in tumor control group to 774.6U/L (p<0.05). In the group of 
tumor bearing mice with morin or quercetin pre-treatment, the serum LDH activities were 
385.7U/L and 283.3U/L respectively (p<0.05). Normal control group exhibited 310.3U/L 
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Fig. 3.8. Effect of morin and quercetin on the release of creatine kinase in HepG2-bearing 
nude mice receiving doxorubicin chemotherapy 
Chemotherapy was given to the HepG2-bearing nude mice for three weeks after the day of 
tumor cell inoculation. The mice had received flavonoids or vehicles orally 30 mins before 
i.v. administration of doxorubicin or vehicles three times per week. Normal control (no 
tumor): PBS+PBS; tumor control: PBS+PBS; PBS+dox： PBS+2mg/l^ dox; mor+dox: 
2mg/kg mor+2mg/kg dox; que+dox: 2mg/kg que+2iVkg dox. The activities of CK in 
serum were determined as described in Materials and Methods. Each value is the averse of 
five determinations (mean±S.D.). Vertical bars are the S.D. There was significant difference 
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Fig. 3.9. Effect of morin and quercetin on the release of lactate dehydrogenase in HepG2_ 
bearing nude mice receiving doxorubicin chemotherapy 
Chemotherapy was given to the HepG2-bearmg nude mice for three weeks after the day of 
tumor cell inoculation. The mice had received flavonoids or vehicles orally 30 mins before 
administration of doxorubicin or vehicles three times per week. Normal control (no 
tumor): PBS+PBS; tumor control: PBS+PBS; PBS+dox: PBS+2mg/kg dox; mor+dox: 
2mg/kg mor+2mg/kg dox; que+dox: 2mg/kg que+2nVkg dox. The activities of LDH in 
serum were determined as described in Materials and Methods. Each value is the average of 
five determinations (mean+S.D.). Vertical bars are the S.D. There was significant difference 
(p<0.05) in Lactate dehydrogenase activity between normal control, tumor control mor+dox, 
que+dox and PBS+dox groups. 
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3.4.7. Effect of morin and quercetin on aspartate transaminase (AST) release in HepG2-
bearing nude mice receiving doxorubicin chemotherapy 
Serum AST activities were similar in normal control and tumor control groups. They 
were 81.9U/L and 83.4U/L respectively (Fig. 3.10.). In the group of dox-alone treatment, 
the activity was found to be 168.6U/L and was significantly elevated (p<0.05). Pre-treatment 
of morin and quercetin could not reduce the elevated AST release caused by doxorubicin. 
The AST activities in these two groups were 150.2U/L and 140.9U/L respectively. There 
was no significant difference among the three dox-treated groups. 
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Fig. 3.10. Effect of morin and quercetin on aspartate transaminase release in HepG2-bearmg 
nude mice receiving doxorubicin chemotherapy 
Chemotherapy was given to the HepG2-bearing nude mice for three weeks after the day of 
tumor cell inoculation. The mice had received flavonoids or vehicles orally 30 mins before 
i-v- administration of doxorubicin or vehicles three times per week Normal control (no 
tumor): PBS+PBS; tumor control: PBS+PBS; PBS+dox： PBS+2mg/kg dox; mor+dox: 
2mg/kg mor+2mg/kg dox; que+dox: 2mg/l^ q u e + l n ^ dox. The activities of AST in 
serum were determined as described in Materials and Methods. Each value is the average of 
five determinations (mean+S.D.). Vertical bars are the S.D. There was significant difference 
(p<0.05) in Aspartate aminotransferase activity between normal control, tumor control and 
PBS + dox groups only. 
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3.4. Discussion 
Nude mice model was used to study the effect of morin and quercetin on 
doxorubicin-induced cardiotoxicity and cytotoxicity. After being inoculated with human 
hepatoma (HepG2) cells, the nude mice received doxorubicin chemotherapy together with 
morin or quercetin. In order to meet the high levels of scavenging and chelating activities of 
these two antioxidants during the early stages of the presence of doxorubicin in the 
myocardium, the mice of two test groups received oral administration of morin and 
quercetin respectively 30 minutes before i.v. doxorubicin were given. 
It was well demonstrated from the results of assays of heart TEARS content that 
morin and quercetin protect the heart from lipid peroxidation dam^e in doxorubicin 
chemotherapy. The heart TEARS contents in morin-test-group and quercetin-test-group 
were 60% and 80% lower than that in the dox-group. The lipid peroxidation induced by 
doxorubicin was minimized by morin and quercetin. Moreover, morin-test-group had 
significantly higher heart GSH content than that of dox-group. Quercetin-test-group also 
exhibited higher heart GSH content than that of dox-group though the difference was 
insignificant. 
However, it was found that the two test-groups exhibited lower heart GSH content 
than those in nonnal and tumor control groups. It may be due to more radical scavengers 
was required to encounter the oxidative challenge induced by doxorubicin in nude mice. 
The activities of heart GRD and GPx showed similar results as the heart GSH contents did 
Their activities in two test-groups were at the levels lower than those in dox-group, but 
higher than those in normal and control groups. The administrated morin and quercetin 
were not enough to scavenge all doxorubicin-generated oxyradicals, and thus GSH were 
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used and the activities of GPx were induced GRD activities were also elevated to 
regenerate GSH from GSSG in order to meet the demand of reduaants. When large 
amount of GPx were used to catalyze the oxidation of GSH hy hydrogen peroxide, the GST 
activities increased to detoxify organic radicals. Therefore, dox-group was found to have a 
significant elevation of GST activity. The two test-groups exhibited low GST activities 
because of their relatively little use of GSH and thus GPx. 
The activities of superoxide dismutase (SOD) in heart of two test-group mice were 
not induced by doxorubicin, although large amount of superoxide radicals were produced. 
It was because the superoxides generated were inactivated by the two flavonoids without any 
catalysis and form hydrogen peroxides. The increase of SOD substrate only appeared in the 
dox-group, and thus its activity was induced. 
The antitumor activity of doxorubicin was not reduced, but enhanced by morin and 
quercetin. After the experiment, the tumor weights in morin-test-group werc 50% less than 
the one in dox-group. Tumors in the quercetin-test-group were nearly eliminated. However, 
morin and quercetin showed little cardio-protective effect against doxorubicin damage other 
than lipid peroxidation as demonstrated in serum AST and CK activities assays in this study. 
There were only insignificant decreases of AST and CK activities in the serum of the mice 
receiving combined treatment. These results differed from the one obtaining in rats in the 
previous chapter. They msy be due to several reasons. First, hearts of rats were found to be 
more resistant to doxorubicin dam^e. Second, mice in this study received more times of 
doxorubicin administration and fewer doses of flavonoids. Furthermore, oral administration 
of flavonoids might not as efficient as i.p. administration. Therefore, the small amount of 
flavonoids cannot overcome the dam^es caused by doxorubicin. A l t ho i ^ serum LDH 
activities in mice receiving combined treatment were found to be significantly decreased in 
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present study, further studies have to be conducted in order to clarify the actual cardiac 
condition in the combined treatment due to the conflict results with the serum AST and CK 
activities. 
Finally, it can be concluded that morin and quercetin protected the heart from 
doxombicin-mediated lipid peroxidation, and at the same time, enhance the antitumor effect 
of doxorubicin. However, the general cardioprotective effect exhibiting by these flavonoids 
has to be further studied. 
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C h ap t e r 4 
STUDY OF THE EFFECT OF FLAVONOIDS O N DOXORUBICIN- INDUCED 
CYTOTOXICITY O N H U M A N TUMOR CELL LINE A N D DOXORUBICIN-
RESISTANT H U M A N TUMOR CELL LINE 
4.1 Introduction 
Doxorubicin kills cells mainly by two mechanisms. One is radical-dependent and the 
other is radical-independent. In the radical-dependent mechanism, doxorubicin generates 
superoxide radicals in its metabolism. The superoxide radicals then form hydrogen peroxide 
and later hydroxyl radical. These oxyradicals cause dam^es on DNA, protein and lipid, and 
thus the cell dies. In the radical-independent mechanism, doxorubicin kills cells by 
intercalating with the DNA or inhibiting the activity of topoisomerase I I which mediates 
DNA break^e-reunion reaction. It is still a doubt that the application of antioxidant in 
doxorubicin chemotherapy may reduce the cytotoxicity. The doubt is based on the fact that 
radical scavenging effect of antioxidants may interfere the radical-dependent cytotoxic 
mechanism of doxorubicin. In this chapter, the cytotoxic effects of doxorubicin with co-
incubation of morin or quercetin on human hepatoma (HepG2) cells were demonstrated 
The cell viabilities were determined by MTT assay. This assay is based on the conversion of 
yellow-coloured tetrazolium, 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) into purple formazan, which shows an absorbance at 540nin, catalyzed by 
dehydrogenase in cell mitochrondria. 
Host receiving prolonged doxorubicin treatment will develop doxorubicin resistance. 
The mechanism of drug resistance involves p-glycoproteins and GST in detoxification 
systems. P-glycoproteins are single chain proteins and consist of approximately 1280 amino 
acid residues. They are composed of two homologous halves each of which contain a 
hydrophobic, membrane-associated domain followed by a hydrophilic nucleotide binding 
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fold. P-glycoproteins are responsible for increasing the rate of drug efflux, so that fewer 
doxorubicin molecules remain in the cells. Glutathione-S-transferase may decrease 
doxorubicin-mduced damage to the cells by catalyzing the conjugation of base propenals, 
which are products of DNA degradation due to hydroxyl radical generation. 
To study the effect of flavonoids on doxorubicin resistance, a doxorubicin-resistant 
cell line HepG2 was developed in our laboratory. Two sets of experiments were done. Cell 
viabilities after combined treatment were determined. Expressions of p-glycoprotein and 
GST in R-HepG2 cells after treatment with morin or quercetin were also investigated by 
SDS-PAGE and antibodies probing. 
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4.2 Materials and methods 
4.2.1 Materials 
4.2.1.1 Cell culture 
Human Hepatoma (HepG2) cells and doxorubidn-resistant human hepatoma (R-
HepG2) cells were grown in 75-cm^ polystyrene flasks (Coming in RPMI 1640 (Gibcobrl), 
FCS (Gibcobrl) and 5% antibiotics (penicillin and streptomycin, Gibcobrl). Cell cultures 
were kept in a humidified atmosphere of 5% CO，and 37°C. Then 1.2uM doxorubicin was 
added into the cell culture medium of R-HepG2 cells to maintain its drug resistance. On the 
day of experiment, the cells were removed from the flasks with tiypsin-EDTA (Gibcobrl). 
They were plated at 2x10' cells per well on 96-well plates (Coming). HepG2 cell line was 
obtained from ATOC. R-HepG2 cell line was developed in our laboratory by incubating the 
HepG2 cells with stepwise increase concentrations of doxorubicin. 
4.2.1.2 Flavonoids 
Pure Morin and Quercetin powder were purchased from Sigma Chemical Company. 
They werc dissolved in DMSO (Sigma, U.SA.) to a concentration of O.IM and diluted to the 
appropriate concentration by the culture medium. 
4.2.1.3 Doxorubicin 
Doxorubicin hydrochloride was purchased from Sigma Chemical Company. It was 
dissolved in culture medium to a concentration of lOOjiM. 
4.2.1.4 Antibodies 
Anti-Glutathione-S-transferase (pl-1) was purchased from Calbiochem. Anti-p-
glycoprotein was purchased from Calbiochem. The anti-rabbit antibodies as the secondaiy 
antibodies of the above two antibodies were also purchased from Calbiochem. 
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4.2.1.5 Chemical 
Cell viability measurement 
3-[4, 5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide solution (MTI) 
3-[4，5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide was dissolved in 
distilled water and then being filter. The solution was kept at 4X： and wanned at 37°C before 
use. 
Protein sample preparation 
Lysis buffer 
Lysis buffer consists of 21|ig/ml Aprotinin, 0.5ug/ml Leupeptin, 4.9mM MgPl2, 
ImM Vanadate, 1% Triton and ImM PMSF. PMSF should be dissolved isopropanol and 
added into the lysis buffer the latest. Others dissolved in distilled water. All ingredients were 
purchased from Sigma, U.S.A. 
2X SDS sample buffer 
1.51g Tris base, 20g Glycerol, 10ml 2-Mercaptoethanol and 4.6g SDS were dissolved 
in 80ml distilled water. The buffer was adjusted to pH6.8 by HCL before adding up to 
100ml. The entire ingredients were purchased from Sigma, U.S.A. 
BCA protein assay Reagent A&B 
BCA protein assay Reagent A & B were purchased from PIERCE. 
Protein stock solution 




8% Acrylamide lower gel solution 
8% Acrylamide lower gel solution was prepared by mixing 7.63 ml distilled water, 
4.27ml 30% Acrylamide，4ml 4X Lower gel buffer (LGB), 18.6ul TEMED (Sigma, U S A ) 
and 80ul 10% Ammonium persulfate (APS) together. 
12% Acrylamide lower gel solution 
12% Acrylamide lower gel solution was prepared by mixing 5.5ml distilled water, 
6.4ml 30% Arylamide, 4ml 4X LGB, 18.6ul TEMED and 80ul 10% APS together. 
4.5% Acrylamide upper stacking gel solution 
4.5% Aciylamide upper stacking gel solution was prepared by mixing 4.8ml distilled 
water, 1.2 ml 30% Aciylamide, 2ml 4X Upper gel buffer, 10.6ul TEMED and 60ul 10% APS 
together. 
30% Acrylamide solution 
30% Aciylamide solution was prepared by dissolving 30g Acrylamide and 0.82g Bis-
aciylamide into 50ml distilled water. The solution was then filter with Whatman #1 filter 
paper and added with distilled water to a final volume of 100ml. 
4X Lower gel buffer (LGB) 
4X LGB was prepared by dissolving 90.8g Tris base and 2g SDS into 400ml distilled 
water. The buffer was then adjusted to pH8.8 with H Q and added up with distilled water to 
500ml finally. 
4X Upper gel buffer (UGB) 
4X UGB was prepared by dissolving 30.3g Tris base and 2g SDS into 400ml distilled 
water. The buffer was then adjusted to pH 6.8 with H Q and added up with distilled water to 
500ml finally. 
87 
SDS Running buffer 
SDS Running buffer was prepared by dissolving 3.03g Tris base, 14.4g Glycine and 
lOg SDS into 1000ml distilled water. 
Molecular weight standard 
High and low MW standard were purchased from BIORAD. 
Electrobloting 
Electroblot buffer 
Elearoblot buffer was prepared by mixing 66.7ml lOX Tris-Glydne, 100ml methanol 
and 500ml distilled water together. 
lOXTris-Glycine 
20X Tris-Glycme was prepared by dissolvii^ 30.3g Tris base and 144g Glycine into 
1000ml distilled water. 
Antibody probing 
lXPBS-0.1% Tween 20 
4L PBS-T was prepared by adding 4ml Tween 20 into 3996ml IX PBS. 
Blot development and detection 
ECL western blotting detection reagent 1 & 2 were purchased from Amersham. 
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4.3.2 Methods 
4.3.2.1 Effect of Flavonoids on doxombicin-induced toxicity 
4.3.2.1.1 Drug treatment 
24 hours after plating the cells, supernatant was removed and replaced by different 
concentration of lOOul doxorubicin or flavonoids. In combined treatment, the first drug 
(50|Ld) was added 1 hour before the second one (50|il). The cells were then kept at a 
humidified atmosphere of 5% CO〗 and 37。C for 24 hours. 
4.3.2.1.2 Cell viability measurement 
Medium was removed and the cells were washed with sterile PBS. Then 50^1 MTT 
solution was added to each well. After two-hour incubation at 37X：, MTT solution was 
removed and 150|il DMSO was added, followed by 15 mins incubation at 37X：. 
Absorbances at 540nm of the cells were finally recorded by an ELISA plate reader (BIO-
RAD). 
4.3.2.2 Effect of Flavonoids on protein expression in R-HepG2 cells 
4.3.2.2.1 Drug treatment 
R-HepG2 cells were grown in 75-cm^ flasks (Coming) and kept under the same 
condition as described in 4.3.1.1. Doxorubicin, morin and quercetin were added as the 
following protocol: 
1) R-HepG2 with no dox medium; 
2) R-HepG2 with 0.5|liM morin; 
3) R-HepG2 with 0.5^M quercetin. 
Cells were kept for four weeks. Fresh drugs and medium were replaced every three 
days. Protein samples were collected every week. 
4.3.2.2.2. Protein samples preparation 
1) Medium was discarded and the cells were washed with sterile PBS twice. 
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2) The cells were removed from the flasks by 2ml trypsin-EDTA. 
3) The reaction was stopped by adding 3ml medium and the mixture was centrifuged at 
HOOOrpm for lOmins. 
4) The cells were washed with PBS and centrifuged at HOOOrpm for lOmins. 
5) The supernatant was removed. 
6) Repeat step 4) & 5) for 3 times. 
7) The cells were lyzed by adding 200ul lysis buffer and incubating for 30 mins at room 
temperature. 
8) The mixtures were boiled for 15 mins. 
9) The protein samples were stored at -70。C. 
4.3.2.2.3. Protein assay 
1) 0.5mg/ml protein stock was made by diluting of lOfil 2nig/ml protein stock 
solution with 30ul distilled water. 
2) Proper amount of protein stock solutions were aliquoted to 96 well plate in triplicate 
as show in following table: 
Protein content Volume of Volume o f V o l u m e of dH，。 
(|ug) 0.5mg/ml 2mg/ml protein (jJ) 
protein stock (|ul) stock (fil) 
0 0 0 10 
05 i 0 9 
2 0 8 
^ 4 0 6 
0 2 8 
^ 0 3 7 
^ 0 4 6 
lOO 0 5 5 
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3) l | i l of the protein sample was aliquoted into the 96 well plate in triplicate and V of 
distilled water was added into each well. 
4) Woiting BCA Protein Assay Recent was prepared by combining Reagent A: 
Reagent B = 50:l 
5) 0.2 ml Working BCA Protein Assay Reagent was added into each well. 
6) The plate was incubated at 37。C for 30 mins. 
7) Absorbance at 540nm was read. 
8) The concentrations of protein were calculated from the standard curve. 
4.3.2.2.4. Protein Electrophoresis 
1) The gel box was set up. 
2) 8% or 12% lower gel together with upper stacking gel were made. 
3) Upper and lower reservoirs were filled with IX SDS running buffer. 
4) The protein samples were adjusted to 30|Lig in 15ul with IX PBS. 
5) 15jnl high MW standard for 8% gels or low MW standard for 12% gels together with 
15|il loading dye were loaded. 
6) 15)LI1 protein samples together with 15[il loading dye were loaded into the wells of the 
stacking gel. 
7) The electrophoresis was started at 200V, constant voltage for 90 mins. 
4.3.2.2.5. Electroblot 
1) Thick blotter paper (6 pieces per gel) and Immobilon-P membrane (1 per gel) were 
prepared. 
2) Immobilon-P membrane for 1-2 seconds was wet in 100% methanol and then was 
place in E-blot transfer buffer for 5 mins. 
3) Gel was rinsed after electrophoresis in E-blot transfer buffer once. 
4) Three pieces of blotter paper were soaked in E-blot transfer buffer and were placed 
onto the platinum anode of the Semi-dry Blotter. 
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5) The E-blot transfer buffer equilibrated membrane was placed on the blotter paper. 
Trapping of air bubbles should be avoided. 
6) The gel was placed on the top of the membrane. Trapping of air bubbles should be 
avoided. 
7) Three pieces of blotter paper were soaked in E-blot transfer buffer and were placed 
onto the gel. 
8) Air bubbles were rolled out. 
9) The cathode and safety cover were placed onto the stack. 
10) Transfer was done at 15V for 1 hour. 
11) The membrane was removed from the Semi-dry Blotter after the transfer. 
12) The membrane was air-dried at room temperature. 
4.3.2.2.6. Antibody probing 
1) The membrane was immersed in methanol for 10 seconds and then into IX PBS for 
1-2 seconds 
2) The membrane was incubated in 5% non-fat dry milk at 4冗 overnight to be 
blocked. 
3) The membrane was rinsed with PBS-T. 
4) The membrane was rocked in PBS-T for 10 mins for three times. 
5) The membrane was rinsed with PBS-T once. 
6) The membrane was placed into 5 ml 5% non-fat diy milk contenting appropriate 
amount of primary antibodies (GST or p-glycoprotein) and rocked for 1 hour. 
7) The membrane was rinsed with PBS-T. 
8) The membrane was rinsed in PBS-T for 10 mins for three times. 
9) The membrane was placed into 5 ml 5% non-fat diy milk contenting appropriate 
amount of secondary antibodies (anti-rabbit antibodies) and rocked for 1 hour. 
10) The membrane was rinsed with PBS-T. 
11) The membrane was rocked in PBS-T for 10 mins for three times. 
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4.3.2.2.7. Detection 
1) ECL Western Blotting Detection Reagents (Amersham) was used to detect the 
antibodies probing. 
2) The instructions on the menu provided with the reagents were followed. 
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4.4. Results 
4.4.1. Effect of flavonoids in doxorubicin-induced toxicity 
4.4.1.1. Parental human hepatoma (HepG2) 
4.4.1.1.1. Effect of doxorubincin on HepG2 cells 
After 24 hours incubation under aerobic condition, the IC50 of doxorubicin (DOX) 
on human hepatoma cells (HepG2) was found to be 9)nM (Fig. 4.1.). 
4.4.1.1.2. Effect of flavonoids on HepG2 cells 
Experimental solvent control was done. The percentage of cell viability remained 
more that 87% when treated with up to 0.5% of DMSO, which was the most concentrated 
DMSO appeared in all of our experiments (Fig. 4.2.). 
In the concentration from 3.125|uM to 200|aM, quercetin strongly inhibited the 
proliferation of HepG2 and exhibited an IC叨 of 16.7— (Fig. 4.4.). With same treatment 
condition, morin was less effective and could only inhibit 40% of the growth of HepG2 cells 
with concentration up to 500幽(Fig. 4.3.). 
These results indicated that HepG2 cells were sensitive to quercetin and much less 
sensitive to morin. 
94 
125 n 
100 I I 
1 7 5 * 
i \ 
® \ 




0 J . r , , r- , 
0 20 40 60 80 100 120 
[dox] (nM) 
Fig. 4.1. Effect of doxorubicin on HepG2 cells 
Different concentrations of doxorubicin, ranging from 1.5625)liM to LOOPM, were added into 
2X104 HepG2 cells. After incubation at 37。C，5% CO〗 for 24 hrs, cell viabilities were 
measured by MTT assay as described in Materials and Methods. Each point was given by the 
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Fig. 4.2. Solvent control on HepG2 cells 
Different concentrations of DMSO, ranging from 0.31% to 10%, were added into 2X10^ 
HepG2. After incubation at 37°C, 5% CO: for 24hrs, cell viabilities were measured by MTT 
assay as described in Materials and Methods. Each point was given by the average of 5 wells 
of the experiment. Vertical bars represented the S.D. of the percentage of cell viability. 
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Fig. 4.3. Effect of morin on HepG2 cells 
Different concentrations of morin (mor), ranging from 15.625nM to SOOpM, were added into 
2X104 HepG2 cells. After incubation at 37。C，5% CO，for 24hrs, cell viabilities were 
measured hy MTT assay as described in Materials and Methods. Each point was given by the 
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Fig. 4.4. Effect of quercetin on HepG2 cells 
Different concentrations of quercetin (que), ranging from 3.125)aM to 200|iM, were added 
into 2X10' HepG2 cells. After incubation at 37。Q 5% CO^ for 24hrs, cell viabilities were 
measured by MTT assay as described in Materials and Methods. Each point was given by the 
average of 5 wells of the experiment. Vertical bars represented the S.D. of the percent喂 of 
cell viability. 
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4.4.1.1.3. Effect of morin on the cytotoxicity of doxorubicin on HepG2 cells 
In the presence of morin, the cytotoxicity of dox was not reduced. Morin solutions 
5〇|il at 200|iM were added 1 hour after 50|il of 0.625|iM to 20mM dox had been added to 
the cells. It was found that lOOfjM morin (final concentration) did not affect the toxicity of 
dox towards HepG2 cells at the concentration between 0.3125|jM and 3|AM (final 
concentration) (Fig. 4.5). However, in the concentration of dox between and lOjoM, the 
addition of morin reduced the viability of doxorubicin-treated HepG2 and gave an IC50 about 
6mM dox. When 50|il of 200|jM morin was added 1 hour before the addition of 50|i 
0.625|aM to 20|aM dox, cytotoxicity of dox between 0.3125|iM and 3[M was not affected 
also. Moreover, the addition of morin together with dox of which concentrations ranging 
from 3|iM to LOJOM reduced more the cell viability and gave an IC50 of 4.2|jM of 
doxorubicin. In general, the pre-treatment of morin exhibited a better performance in the 
combined treatment with doxorubicin in killing HepG2. 
On the other hand, the cytotoxicity of dox towards HepG2 was not altered by 
mor in concentrations rangbg from 7.8125_ to 250mM (Fig. 4.6)，no matter they were 
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Fig. 4.5 Effea of morin on the cytotoxicity of different concentration of dox on HepG2 
cells 
X : dox alone; • : 50^1 200|jM morin added Ihr after the addition of 50|il 0-20|aM dox; • 
:50pl 200mM morin added 1 hr before the addition of 50|il 0-20pM dox. After incubation at 
:37°C，5%C02 for 24hrs, cell viabilities were measured by MTT assay as described in Materials 
and Methods. Results were presented with final concentrations. Each point was given by the 
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Fig. 4.6 Effect of different concentration of morin on the cytotoxicity of 3|jM dox on 
HepG2 cells 
• :50}il 6pM dox added Ihr before the addition of 50|ul 0-500|jM morin； •: 50 1^ 6|jM dox 
added 1 hr after the addition of 50|i 0-500|aM morin. After incubation at 37°C, 5%C02 for 
24hrs，cell viabilities were measured by MTT assay as described in Materials and Methods. 
Results were presented with final concentrations. Each point was given by the average of 5 
wells of the experiment. Vertical bars represented the S.D. of the percentage of cell viability. 
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4.4.1.1.4. Effect of quercetin on the cytotoxicity of doxorubicin on HepG2 cells 
The viability of HepG2 cells was reduced in the presence of quercetin (que) and 
doxorubicin. When 50}J of 5 0 _ que was added to the cellsl hour after the addition of 50|i 
of 0.625mM to 20juM dox (final concentration: 25|jM que and 0.3125 to LOJJM dox), the 
number of survived HepG2 cells decreased. It gave an IC50 of 6|jM dox (Fig. 4.7). In 
another experiment, 50 1^ of 50|AM que was added 1 hour before 50|i of 0.625|liM to 2 0 _ 
dox was added to the HepG2 cells. It was found that the pre-treatment of que exhibited a 
better performance in combined treatment to kill the HepG2 cells and gave an IC50 of 3|jM 
dox (Fig. 4.7). 
In the experiments of studying the effect of different concentrations of que in 
combined treatment with 3|uM doxorubicin (final concentration) on HepG2 cells, the cell 
viability decreased in que-dose dependent maimer (Fig. 4.8). Que showed synergistic effect 
with dox on killing HepG2 cells. It was also found that pre-treatment of que gave a better 
performance on cytotoxicity on HepG2 cells than treatment after the addition of dox 
although they had similar IC50 (25|aM). 
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Fig. 4.7 Effect of que on the cytotoxicity of different concentration of dox on HepG2 
X: dox alone; • : 50|il 50|LIM que added Ihr after the addition of 50|il 0-20|JM dox; •: 50|LD 
50|jM que added 1 hr before the addition of SOjol 0-20|aM dox. Results were presented with 
final concentrations. After incubation at 37。C，5%C02 for 24hrs, cell viabilities were 
measured by MTT assay as described in Materials and Methods. Each point was given by the 
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Fig. 4.8 Effect of different concentration of que on the cytotoxicity of 3)nM dox on HepG2 
• : 50|LI1 6|LIM dox added Ihr before the addition of 50|il 0-200|JM que; •: 50|il 6MM dox 
added 1 hr after the addition of 50)al 0-200|uM que. Results were presented with final 
concentrations. After incubation at 37。C，5%C02 for 24hrs, cell viabilities were measured by 
MTT assay as described in Materials and Methods. Each point was given by the averse of 5 
wells of the experiment. Vertical bars represented the S.D. of the percentage of cell viability. 
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4.4.1.2. Doxorubicin-resistant human hepatoma (R-HepG) cells 
4.4.1.2.1. Effect of doxorubicin on R-HepG2 cells 
After 24 hours incubation under aerobic condition, it was found that R-HepG2 cells 
exhibited only very little sensitivity towards dox-treatments up to 200|jM of dox, 
i.e.IC5o>200|LiM dox (Fig. 4.9). 
4.4.1.2.2. Effect of flavonoids on HepG2 cells 
Experimental solvent control was done. The percentage of cell viability did not 
decrease when treated with up to 0.5% of DMSO, which was the most concentrated DMSO 
appeared in all of our experiments (Fig. 4.10). 
In the concentrations from 3.125|aM to lOO^M, quercetin strongly inhibited the 
proliferation of HepG2 cells and exhibited an IC50 of 45|uM (Fig. 4.12). However, when the 
concentrations of quercetin more than 100|jM, the viability of R-HepG2 cells increased 
agaia With same treatment condition, morin was less effective and exhibited an IC50 at the 
concentration of 475^M (Fig. 4.11). 
These results indicated that an R-HepG2 cell was sensitive to quercetin but only 
moderately sensitive to morin. 
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Fig. 4.9 Effect of doxorubicin on R-HepG2 cells 
Different concentrations of doxorubicin, ranging from 6.25|jM to 2 0 0讽 were added into 
2X104 R-HepG2 cells. After incubation at 37°Q 5%C02 for 24hrs, cell viabilities were 
measured by MTT assay as described in Materials and Methods. Each point was given by the 
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Fig. 4.10 Solvent control on R-HepG2 cells 
Different concentrations of DMSO, ranging from 0.156% to 10%, were added into 2X10' R-
HepG2 cells. After incubation at 37°Q 5%C02 for 24hrs, cell viabilities were measured by 
MTT assay as described in Materials and Methods. Each point was given by the averse of 5 
wells of the experiment. Vertical bars represented the S.D. of the percentage of cell viability. 
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Fig. 4.11 Effect of morin on R-HepG2 cells 
Different concentrations of morin, ranging from 15.625|iM to SOOpM, were added into 
2X10' R-HepG2 cells. After incubation at 37°C, 5%C02 for 24hurs, cell viabilities were 
measured by MTT assay as described in Materials and Methods. Each point was given by the 
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Fig. 4.12 Effect of quercetin on R-HepG2 cells 
Different concentrations of quercetin, ranging from 3.125|IM to 200|jM, were added into 
2X10' R-HepG2 cells. After incubation at 37°C, 5%C02 for 24hrs, cell viabilities were 
measured by MTT assay as described in Materials and Methods. Each point was given by the 
average of 5 wells of the experiment. Vertical bars represented the S.D. of the percent堪e of 
cell viability. 
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4.4.1.2.3. Effect of morin on the cytotoxicity of doxorubicin on R-HepG2 cells 
The cytotoxic effect of dox on R-HepG2 cells was not affected in the presence of 
morin. It is shown in Fig. 4.13 that adding 50|LI1 of 200pM morin 1 hour before or after the 
addition of 50|al of different concentrations of dox (final concentration: lOOjoM morin and 
3.125[IM to 100|JM dox) could not improve the insensitivity of R-HepG2 towards dox. The 
viabilities of the cells were not reduced. 
It was further confirmed that the insensitivity of R-HepG2 cells towards 3\iM dox 
could not be improved by 7.8125)LIM to 250|IM morin (Fig. 4.14). 
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Fig. 4.13 Effect of morin on the cytotoxicity of different concentration of dox on R-HepG2 
cells 
X: dox alone; • : 50^ 1 2 0 0 _ morin added Ihr after the addition of 50|al 0-20MM dox; •: 
50^1200^iM morin added 1 hr before the addition of 50^il 0 - 2 0 _ dox. After incubation at 
37X：，5%C02 for 24hrs, cell viabilities were measured by MTT assay as described in Materials 
and Methods. Results were presented with final concentrations. Each point was given by the 
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Fig. 4.14 Effect of different concentration of morin on the cytotoxicity of dox on R-
HepG2 cells 
• : 50^1 6|iM dox added Ihr before the addition of 50|il 0-500|aM morin; •： 5 0 - 6pM dox 
added 1 hr after the addition of 50|il 0-500|uM morin. After incubation at 37^, 50/0CO2 for 
24hrs，cell viabilities were measured by MTT assay as described in Materials and Methods. 
Results were presented with final concentrations. Each point was given by the average of 5 
wells of the experiment. Vertical bars represented the S.D. of the percentage of cell viability. 
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4.4.1.2.4. Effect of quercetin on the cytotoxicity of doxorubicin on R-HepG2 cells 
In the combined treatment of 25^M que with different concentrations of dox, the 
viabilities of R-HepG2 cells reduced • It is shown in Fig. 4.15 that adding 50|il 50|aM que 1 
hour before or after the addition of 50|al of different concentrations of dox (final 
concentration: lOOpM que and 3.125nM to 100)aM dox) effectively reduced the viabilities of 
R-HepG2 cells. However, the insensitivity of R-HepG2 cells towards dox was not yet been 
improved. Que showed synergistic effect with dox on killing R-HepG2 cells. It was also 
found that the R-HepG2 cells viabilities in combined treatment of 3|JM dox with que 
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Fig. 4.15 Effect of que on the cytotoxicity of different concentration of dox on R-HepG2 
cells 
X: dox alone; • : 50|al 50|JM que added Ihr after the addition of 50}i 0-20|JM dox; •: 50|i 
50MM que added 1 hr before the addition of 50|LI1 0 - 2 0 _ dox. After incubation at 37°Q 
5%C02 for 24hrs, cell viabilities were measured by MTT assay as described in Materials and 
Methods. Results were presented with final concentrations. Each point was given by the 
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Fig. 4.16 Effect of different concentration of que on the cytotoxicity of 3|iM dox on R-
HepG2 cells 
• : 50|al 6|LIM dox added Ihr before the addition of 50}il 0-200)JM que;參：5〇|al 6|JM dox 
added 1 hr after the addition of 50^1 0-200|iM que. After incubation at 37X； 5%C02 for 
24hrs，cell viabilities were measured by MTT assay as described in Materials and Methods. 
Results were presented with final concentrations. Each point was given by the averse of 5 
wells of the experiment. Vertical bars represented the S.D. of the percentage of cell viability. 
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4.4.2. Effect of flavonoids on protein expressions on R-HepG2 
The results of Western blottings werc shown in Fig. 4.17 and 4.18. All the results 
were summarized in table 1. To maintain the resistance, R-HepG2 cells were kept with 
1.2|uM dox. When they were kept without doxorubicin for 1 week, 32% decrease of p-
gjycoprotein was observed The p-glycoprotein expression had a total 63% decrease after 
such condition had been maintained for 4 weeks. After the R-HepG2 cells had been treated 
with 0.5uM morin for 1 week and 4 week, their p-glycoprotein expression was found to have 
55% and 77% decrease respectively. The expression of p-glycoprotein in R-HepG2 after 1-
week treatment with 0.5|aM was 48% of the normal expression. However, when the 
treatment last for 4 weeks, the expression, which was 44%, was not changed at all. 
R-HepG2 cells were found to have 28% more GST than the parental HepG2 cells. 
When the R-HepG2 cells had been kept without doxorubicin, the expression of GST did not 
change. After 1 week, there was 40% decrease. The expressions of GST remained similar as 
control after 1-week treatment with 0.5|uM morin and quercetin. After 4 weeks, the GST 




treatment p-glycoprotein GST 
HepG2 control - 72.9 
R-HepG2 control 100 
No dox for 1 week 100.8 
No dox for 4 weeks 37.4 60.7 
0.5|LIM mor for i week 100^ 
O.Sf^ M mor for 4 weeks 23.4 5^9 
0.5|iM que for 1 week 1013 
0.5|aM que for 4 weeks 44.3 32^ 
Table 1. Expression of p-glycoprotein and GST in R-HepG2 cells after different treatments. 
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Fig. 4.17 Western Blotting of p-glycoprotein expression in R-HepG2 cells after different 
treatments. 
Lane 1: HepG2 control 
Lane 2: R-HepG2 control 
Lane 3: no dox for 1 week 
Lane 4: no dox for 4 weeks 
Lane 5: 0.5|iM mor for 1 week 
Lane 6: 0.5)LIM mor for 4 weeks 
Lane 7: 0.5^M que for 1 week 
Lane 8: 0.5)uM que for 4 weeks 
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Fig. 4.18 Western Blotting of GST expression in R-HepG2 cells after different treatments. 
Lane 1: HepG2 control 
Lane 2： R-HepG2 control 
Lane 3: no dox for 1 week 
Lane 4: no dox for 4 weeks 
Lane 5: 0.5|iM mor for 1 week 
Lane 6: 0.5fiM mor for 4 weeks 
Lane 7: 0.5|iM que for 1 week 
Lane 8: 0.5)LIM que for 4 weeks 
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4.4. Discussion 
In addition to antioxidant effect, morin and quercetin showed antiproliferative effect 
on HepG2 cells. This effect in quercetin was so strong that it exhibited IQQ of 16.7|iM 
Morin did much weaker effect, its IC，。was found to be greater than 500fiM. 
In the co-incubation of quercetin and doxorubicin, quercetin was found to enhance 
the cytotoxicity on HepG2 cells dose-dependently. When quercetin was added 1 hour before 
doxorubicin addition, a stronger cytotoxicity was perforaiecL On the other hand, morin 
exhibited no effect on low concentration doxorubicin cytotoxicity. It enhanced the killing 
effect in a dose-independent manner when the concentration of doxorubicin was greater than 
3)LIM. Better performance was observed in pre-treatment of morin. 
The doxombicin-resistant HepG2 (R-HepG2) cells were found to have no response 
to doxorubicin. However, quercetin killed R-HepG2, giving an IC刃 of 45|JM; while R-
HepG2 had no response toward morin. Quercetin enhanced the cytotoxicity in doxorubicin 
cotreatment on R-HepG2 cells, as in HepG2 cells, in a dose-dependent manner. Morin still 
showed no effect on R-HepG2 cells in doxorubicin-combined treatment. 
The cytotoxic effects of doxorubicin were not reduced by the two antioxidants morin 
and quercetin under aerobic condition, which favours the induction of free radicals by the 
drug action of doxorubicin. The cytotoxicities were not reduced because morin and 
quercetin only stabilized the free radicals induced by doxorubicin, but could not conjugate to 
the active intermediates of doxorubicin, which intercalated the DNA of the cells and killed 
them. The enhancement of cytotoxicity on HepG2 cells and R-HepG2 cells in the combined 
treatment were not probably due to direct action of the two flavonoids to doxorubicin, but 
synergistic effect. Quercetin and morin could kill tumor cells, and thus they may 
synergistically kill the cells with doxorubicin. Since the R-HepG2 cells were aggressive due to 
their drug resistance system, it was already expected that more flavonoids were required 
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There was no evidence that quercetin and morin could improve the doxorubicin sensitivity in 
R-HepG2 cells. 
It has been stated that p-glycoprotein and GST are involved in drug resistance 
system. Expressions of such two proteins in R-HepG2 after receiving morin and quercetin 
treatments were studied in order to investigate the effect of these two flavonoids on drug 
resistance system. It was found that morin could reduce the expressions of both GST and p-
glycoprotein in the cells. However, quercetin reduced only GST expression. Quercetin could 
decrease the p-glycoprotein expression at week 1, but then exhibit no effect on the later 3 
weeks. It may be because quercetin, which has antitumor effect，was treated as substrate of p-
glycoprotein after the 1-week treatment. Further experiments have to be done in order to 




The present studies reveal that the two flavonoids, morin and quercetin, protected the 
heart from doxorubicin-induced damage, and at the same time, enhanced the antitumor 
abilities of doxorubicin. On the other hand, they could kill cancer cells and reduce the 
expression of some proteins that involve in drug resistance in the multidrug resistant tumor 
cells. 
Cardioprotective effect 
The cardioprotective effect of morin and quercetin was believed to be the results of 
radical scavenging ability in their antioxidative effects. In the SD rats model, the oxyradicals 
generated by doxorubicin were scavenged by morin and quercetin. The end products of lipid 
peroxidation, TEARS and MDA, were at normal level in heart. Serum CK and LDH 
activities were also found to be normal. These indicated that doxombidn caused no lipid 
peroxidation and damages in heart when morin and quercetin were administrated 30 minutes 
before the i.v. injection of doxorubicin. Moreover, the administrations of morin and 
quercetin preserved the antioxidant capacity of the heart. GSH consumption in encountering 
with dox-induced oxyradicals was very low that the activities of GPx, which catalyzes the 
reaction between GSD and hydrogen peroxide, and GRD, which is responsible for the 
regeneration of GSH from GSSG, were not induced. The oxyradicals were scavenged by 
morin and quercetin directly. However, these two flavonoids antioxidants exhibited litde 
effect on the general protection against doxombidn damage. General toxic sign evidenced by 
a significant impairment of body weight gain was found in the SD rats received doxorubicin-
flavonoid combined treatments. 
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In tumor-bearing mice model, it was further demonstrated that the cardioprotective 
effect of morin and quercetin against doxorubicin-mediated lipid peroxidation was due to 
their radical scavenging abilities. Tumor-bearing mice receiving doxorubicin chemotherapy 
together with morin and quercetin exhibited no heart damages caused by lipid peroxidation, 
but associated with GSH depletion as well as GPx and GRD activities elevation. It was 
believed that morin and quercetin scavenged the oxyradicals generated in the metabolism of 
doxorubicin prior to the action exerted by endogenous antioxidant, GSH. When the amount 
of morin and quercetin were not enough to encounter all the oxyradicals, GSH were used. 
GPx and GRD activities were thus increased. This may be the reason of the different 
activities of GRD and GPx between SD rats and tumor-bearing models, although there was 
species difference between these two animal models so that they could not be compared 
directly. Morin and quercetin consumed the superoxide radicals by their radical scavenging 
abilities, and so the activity of superoxide dismutase was not increased. Although these two 
flavonoids protected the heart from lipid peroxidation effectively，their effects seemed not 
enough to protect the heart from doxorubicin damages other than lipid peroxidation. 
Antitumor effect enhancement 
In the same tumor-beaiing mice model, morin and quercetin enhanced the antitumor 
effect of doxorubicin. Tumor weights in the mice receiving doxombin chemotherapy 
together with these two antioxidants were found to be much less than the one in dox-control 
mice. In ikro study, morin was found to have antiproliferative effect on HepG2 and R-
HepG2 cells. Morin did not reduce the cytotoxicity of doxorubicin on HepG2 and R-
HepG2 cells although doxorubicin still could not kill R-HepG2 cells. However, when the 
concentrations of doxorubicin were up to 3uM, morin enhanced the doxorubicin cytotoxicity 
dose-independently. Pre-treatment with morin did better in the enhancement. 
Quercetin exhibited cytotoxic effect on both HepG2 and R-HepG2 in vitro. It 
showed IC50 of 16.7uM and 45uM on HepG2 and R-HepG2 cells respectively. Therefore, 
quercetin showed synergistic effect with doxorubicin to kill HepG2 and R-HepG2 cells. Pre-
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treatment of quercetin in the co-incubation with doxorubicin was found to exhibit better 
cytotoxicity. 
Morin and quercetin did not affect the dominant killing mechanism, which is based 
on intercalation with DNA molecules and inhibition of topoisomerase II，of doxorubicin. 
Therefore, it can be further confirmed that when these two antioxidants were applied to 
protect the heart from doxorubicin damage, the antitumor effect would not be reduced. 
Effect on expression of drug resistance involved protein in R-Hep2 cells 
Decreasing the expression of drug resistance involved protein which may facilitate 
increasing the sensitivity of R-HepG2 cells to the drug. It was shown that morin and 
quercetin could reduce the expression of GST in R-HepG2 cells. Morin could also reduce 
the p-gjycoprotein expression effectively. However, quercetin could only moderately 
suppress R-HepG2 cells to express p-glycoprotein. It may be due to the potent cytotoxic 
effect of quercetin on R-HepG2 cells. Quercetin may become one of the substrates of p-
glycoprotein. Further experiments have to be done to study the effect of reduced expression 
of such proteins on the drug resistance in R-HepG2 cells. 
As a conclusion, morin and quercetin were found to be good cardio-proteaors 
against doxorubicin damage in present study. Quercetin could also exhibit synergistic effect 
with doxorubicn on cytotoxicity. Moreover, these two flavonoids could reduce GST and p-
glycoprotein expression so that drug resistance may be reduced. 
Future prospects 
It has been already demonstrated that morin and quercetin protect the heart from 
doxorubicin caused lipid peroxidation effectively. However, it seemed that they exhibit mild 
effect on general cardio-protection. In the future, higher doses of morin and quercetin can 
be applied to study if the general cardio-protective effect is improved. Judgii^ from the fact 
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that quercetin possesses antitumor ability, dose of doxorubicin can be reduced in the co-
treatment and thus same antitumor effect will obtain with lower adverse side effects. 
Moreover, administration schedule can be altered so that maximum antitumor effect and 
minimum adverse side effect will obtain. 
Further studies should be carried out to find if morin and quercetin could reduce the 
expression of other drug resistance involved proteins. Experiments demonstrating the effect 
of reduced expression of such proteins on drug resistance should also be performed. 
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